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Introduction
1INTRODUCTION
Treatment options for liver metastases
As a common deposit for tumor cells, the liver is second only to the lymph nodes as 
a site of metastatic disease (1, 2). Unfortunately, by the time patients present with 
liver metastases there is usually evidence of the systemic spread of the disease, and 
patients can not longer be considered as candidates for surgery or other local ablative 
treatments. 
Because the liver is the fi rst major organ reached by venous blood draining from 
the intestinal tract, it is the most common site of metastatic disease in cancers of the 
large intestine (2). It is involved in as many as 50-70% of colorectal cancer patients 
who develop metastatic disease, in approximately half of whom it is the only site of 
recurrence (3).
While the role of local treatments such as surgery and radiofrequency ablation (RFA) 
is relatively well defi ned for colorectal metastases, their indications and benefi ts are 
less clear in metastases from other tumor types (2, 4). However, due to concomitant 
medical diseases or to poor anatomical location or performance status, few patients 
with colorectal liver metastases are considered eligible for resection (5, 6). 
For those patients who are not candidates for surgery, RFA is emerging as an alterna-
tive curative option. But while RFA is the commonest used non-surgical technique for 
local therapy of colorectal liver metastases, it can be hampered by various problems 
involving the location of the tumors within the liver, particularly those adjacent to the 
large hepatic vessels (7). Although large blood vessels adjacent to a tumor are not 
likely to be injured during an ablation, the blood fl ow acts like a heat sink, making it 
more diffi cult to heat the portion of the tumor directly adjacent to the blood vessel.
Ablation of tumors located near the portal vein pedicles is also associated with 
increased complications, as RFA in this area can cause main injury to a major bile duct, 
resulting in biliary stricture. Similarly, due to the risk of thermal injury to adjacent 
organs, subcapsular tumors are also problematic (8). Another point of concern is the 
chance of incomplete ablation in tumors over 3 cm (9). Although larger tumors can 
be treated by overlapping ablations, the likelihood of incomplete ablation seems to in-
crease as tumor size increases (10-13). To introduce a new “bipolar” system that may 
provide better local control than the conventional “monopolar” system when treating 
larger lesions, several modifi cations of the needle electrodes have been developed to 
improve the coagulative capacity of the probes (14).
The positive effects of chemotherapy are well documented for patients with advanced 
colorectal cancer, whether or not the disease is confi ned to the liver (15). Due to their 
improved effi cacy, modern chemotherapy regimes such as FOLFOX, FOLFIRI or XELOX 
combined with bevacizumab can make unresectable disease resectable (16, 17).
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1 Treatment options for hepatocellular carcinoma
Primary liver cancer, particularly hepatocelular carcinoma (HCC), is a major health 
problem worldwide (18). In 80% of cases, HCC develops in cirrhotic livers. In Western 
countries, infection with the hepatitis C virus is the main risk factor, together with 
other causes of cirrhosis, such as alcohol (19, 20). The presence of underlying cirrhosis 
is important, as it interferes with the treatment options and also infl uences survival. 
Several authors have endorsed the staging and treatment algorithm of HCC from the 
Barcelona Clinic Liver Cancer Group as the best tool for management (Figure 1) (21).
Fig. 1. Barcelona Clinic Liver Cancer staging system and treatment allocation. PST=performance status. N1=lymph 
node involvement. M1=metastatic spread. RFA=radiofrequency ablation. TACE=transarterial chemoembolisation. 
(From Bruix J et al. http://www.aasld.org/practiceguidelines/. Reproduced and modifi ed with permission of the 
author).
Hepatic resection has been the primary treatment for HCC in selected patients with 
limited disease; it is preferred for HCC patients with non-cirrhotic livers or selected 
patients with Child-Pugh A cirrhosis. Unlike liver transplantation, it does not treat the 
underlying cirrhosis present in the remnant liver. Tumor recurrence is also greater after 
resection (22). Candidates for liver transplantation are preferably those with cirrhosis 
and a tumor that complies with the Milan criteria (single tumor <5 cm or 1-3 tumors 
each of <3 cm). Liver transplantation reduces the risk of recurrence and de novo HCC 
in the remnant liver, and reestablishes a normal liver function. 
Because most HCC patients are not amenable to resection or liver transplantation, 
RFA has emerged as an effective treatment option for patients who are not eligible for 
surgery. It can also be used as a bridge for patients who are waiting for liver transplan-
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1tation. As with the treatment of liver metastases, RFA is limited by the location of the 
tumor in the liver, and possibly by the tumor size (9, 22-24). In a randomized study, 
RFA has shown to be signifi cantly superior to PEI with respect to local recurrence-free 
survival rates for small HCC (25).
Patients with tumors at an intermediate stage (large or multifocal tumors without 
vascular invasion or extrahepatic disease, well preserved liver function, and absence 
of symptoms) are the best candidates for transarterial chemoembolization (TACE) (21, 
26, 27). What makes TACE relatively safe is the liver-unique vascular supply from the 
portal vein, whereas HCC is supplied almost entirely by branches of the hepatic artery 
(23). Although TACE is the preferred treatment for palliation of HCC, it may be used 
to downstage a tumor prior to resection or RFA, or as a bridge to liver transplantation. 
Patients with locally advanced HCC who are not candidates for a local therapy 
modality, or those with metastatic disease and Child-Pugh A cirrhosis, can benefi t 
from Sorafenib, a multikinase inhibitor with antiproliferative and antiangiogenic activ-
ity (28, 29). Although it has been suggested that patients with Child-Pugh B cirrhosis 
up to 7 points might benefi t from Sorafenib, further data is needed to confi rm its 
safety and benefi t in patients with poorer liver function (21, 29). Combinations of 
local therapies with Sorafenib are currently being investigated (30, 31).
Growing evidence suggests that radioembolization with 90Ytrium is a safe and ef-
fective modality for treating HCC and liver metastases; to date its results have been 
promising. Possible indications may be bridging or downstaging to transplantation or 
resection, as well as palliation in patients with multifocal disease (32-35).
Stereotactic body radiation therapy for liver tumors
External beam radiotherapy had been considered to have a very limited role in the 
treatment of liver tumors. This is due to the evidence that conventional fractionation 
could safely treat the whole liver in doses of up to only 30 Gy, and that such doses 
could lead only to the short-term palliation of symptoms (36, 37). The technical devel-
opment of 3D conformal radiotherapy in the 1980s renewed interest in the treatment 
of primary and metastatic liver tumors. 
In the 1990s, new strategies were developed for treating liver tumors with radio-
therapy alone or in combination with hepatic arterial chemotherapy (38, 39). This work 
was done mainly by two groups, in Michigan and Stockholm, who demonstrated that 
the delivery of high doses of radiation to limited volumes of the liver had promising 
results in terms of local control and survival at an acceptable toxicity. To adapt the 
principles of intracranial radiosurgery for tumors in the body, the Karolinska group 
developed a stereotactic body frame (SBF) which was used for patient fi xation and 
precise tumor localization during planning and treatment (Figure 2).
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Fig. 2. Stereotactic body frame (dummy patient).
The treatment was delivered in one to four treatment fractions (40). To determine the 
reproducibility of the target in the stereotactic system for the fi rst patients, computer 
tomography (CT) examinations were performed. These measurements showed that 
a margin of 5mm in the transversal plane and 10mm in the cranial-caudal direction 
around the tumor compensated for 95% of the tumor deviations from the planning 
CT in the axial plane, and for 89% in the cranial-caudal plane (41). 
The treatment was delivered using a conformal technique in which several copla-
nar or noncoplanar stationary beams created a steep gradient of dose falloff at the 
interface between tumor and normal tissues (40). Generally, a heterogeneous dose 
distribution within the planning target volume (PTV) was used, in which the central 
parts of the PTV received a dose almost 50% higher than the dose prescribed for the 
periphery. The fi rst rationale behind this method was to minimize the dose delivered 
to the normal tissues outside the target. The second rationale was to overcome the 
radioresistance caused by hypoxia, which is presumably present mainly in the central 
areas of the tumors. Thus, for a given dose at the periphery, an increase in dose to the 
central parts of the PTV would increase the therapeutic ratio (42). 
Over the following decade, this concept of stereotactic radiotherapy was further de-
veloped at several other centers. In Europe, two German groups successfully con tinued 
developing the stereotactic method for liver tumors (43, 44). The Michigan group 
also studied the factors infl uencing the liver toxicity associated with radiotherapy or 
radiation-induced liver disease. Their fi ndings suggested that, due to the presence 
of preexisting cirrhosis or hepatitis, the liver of most patients with HCC had a lower 
tolerance to radiation than the liver of patients with metastases (45). 
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1Methods that use a small number of fractions with a high degree of precision 
to deliver a high dose of radiotherapy to a target in the body are now known as 
stereotactic body radiation therapy (SBRT) (46). Generally, this treatment option for 
primary (mainly HCC) and metastatic liver tumors is offered as an ablative radical local 
treatment for patients who are not eligible for surgery or RFA.
Recently, technical advances have been introduced to implement stereotactic treat-
ments. They include frequent imaging during the course of radiotherapy to correct for 
the day-to-day variation in tumor position (image-guided radiotherapy), and advances 
in radiotherapy planning (IMRT and adaptive radiotherapy). 
Aims and outline of the thesis
Over recent years, several groups have reported their experience with regard to 
feasibility and clinical outcomes in the emerging fi eld of stereotactic body radiation 
therapy (SBRT) for liver tumors. However, nothing was known about the impact of 
the treatment in the patient’s quality of life; very little was known about the effect of 
the daily tumor setup corrections on the organs at risk and about the correlation be-
tween imaging and pathology or the microscopic extension for liver metastases. There 
was also very little literature that sought to improve the quality of the treatment by 
comparing different treatment planning strategies. Similarly, there was no completely 
separate analysis within the liver metastases group that reported specifi cally for the 
metastases of colorectal primary only. 
The aim of this thesis was thus to assess the clinical outcomes of SBRT for liver 
tumors at our institution, and to investigate both the quality of SBRT and potential 
methods for its improvement.
In Chapter 2 we present a phase I-II study conducted at our clinic on SBRT for HCC 
and liver metastases. We report feasibility and local control results. In Chapter 3 we 
investigated the impact of the treatment on the patients’ quality of life.
Chapter 4 explores our use of an automated optimization method developed in house 
for beam orientation and weight selection (Cycle) to improve stereotactic treatments. 
Chapter 5 measures the impact of our daily tumor-based setup corrections on the 
dose delivered to the target volume and the organs at risk during SBRT.
Chapter 6 analyzes our long-term results on local control, survival and toxicity of 
patients treated with SBRT for colorectal liver metastases. 
Chapter 7 studies the correlation between MRI and pathology tumor dimensions, and 
establishes the microscopic tumor extension of colorectal liver metastases.
Chapter 8 is a general discussion in which we forecast future developments in the 
fi eld of SBRT for liver tumors.
Chapter 9 is a short summary that includes the studies described in this thesis.
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ABSTRACT
The feasibility, toxicity and tumor response of stereotactic body radiation therapy 
(SBRT) for treatment of primary and metastastic liver tumors was investigated. From 
October 2002 until June 2006, 25 patients not suitable for other local treatments 
were entered in the study. In total 45 lesions were treated, 34 metastases and 11 
hepatocellular carcinoma (HCC). Median follow-up was 12.9 months (range 0.5-31). 
Median lesion size was 3.2 cm (range 0.5-7.2) and median volume 22.2 cm3 (range 
1.1-322). Patients with metastases, HCC without cirrhosis, and HCC < 4cm with cir-
rhosis were mostly treated with 3 x 12.5 Gy. Patients with HCC ≥ 4cm and cirrhosis 
received 5 x 5 Gy or 3 x 10 Gy. The prescription isodose was 65%. Acute toxicity 
was scored following the Common Toxicity Criteria and late toxicity with the SOMA/
LENT classifi cation. Local failures were observed in two HCC and two metastases. 
Local control rates at 1 and 2 years for the whole group were 94% and 82%. Acute 
toxicity grade ≥ 3 was seen in four patients; one HCC patient with Child B developed 
a liver failure together with an infection and died (grade 5), two metastases patients 
presented elevation of gamma glutamyl transferase (grade 3) and another asthenia 
(grade 3). Late toxicity was observed in one metastases patient who developed a 
portal hypertension syndrome with melena (grade 3). SBRT was feasible, with accept-
able toxicity and encouraging local control. Optimal dose-fractionation schemes for 
HCC with cirrhosis have to be found. Extreme caution should be used for patients 
with Child B because of a high toxicity risk.
Acknowledgements: The authors would like to thank P.T.N. Pattynama M.D., Ph.D. 
and S. Dwarkasing, M.D., for their valuable contributions.
Alejandra Mendez bw.indd   20 03-02-11   13:23
21
SBRT for primary and metastatic liver tumors
2
INTRODUCTION
Hepatocellular carcinoma (HCC) and colorectal cancer are among the fi ve most com-
mon causes of cancer mortality in the world (1). As many as 50-70% of patients diag-
nosed of colorectal cancer will present liver involvement during follow-up, being the 
only site of recurrence in half of these patients (2). Surgery is accepted as a potentially 
curative option with survival rates at 5 years of 50-70% for early diagnosed HCC, and 
25-35% for liver metastases when disease is confi ned to the liver (2-5). However, the 
majority of patients are not eligible for surgery because of liver function impairment, 
diminished liver function capacity after several resections, location of the lesion in 
centrally located segments or concomitant medical diseases (4-6). For patients who 
are not suitable for surgery, other local treatment methods, especially radiofrequency 
ablation (RFA) are emerging as alternative curative options but, the proximity of the 
lesion to the gall bladder or main vessels, the subdiaphragmatic location, or the pres-
ence of a non-echogenic lesion (for ultrasound-guided RFA) constitute major problems 
to apply this treatment (7). Radiotherapy, alone or in combination with transarterial 
chemoembolization has become a potential new treatment option for primary and 
metastatic liver tumors around the world (8-10). Stereotactic body radiation therapy 
(SBRT) has no strict restrictions regarding lesion location, and offers the possibility of a 
high precision non-invasive treatment, using small margins (11). The aim of this paper 
was to assess feasibility, toxicity and tumor response of SBRT as a new local treatment 
modality for primary and metastatic liver tumors in our patient population.
MATERIALS AND METHODS
Patient characteristics
Patients included were those with primary or metastatic tumors confi ned to the liver, 
and not eligible for surgery or other local treatment (RFA). The Karnofsky index was at 
least 80%. The Child-Pugh grade for HCC patients was A-B. With the maximum lesion 
size allowed being 7 cm, a maximum of three lesions was acceptable for the protocol. 
Tables 1 and 2 summarize the patient characteristics of this study. From October 
2002 until June 2006, eight patients were treated for 11 primary liver tumors (HCC) 
and 17 patients for 34 metastases. Median age was 63 years (range 37-81). Gender 
distribution was fi ve females, 20 males. Median tumor size was 3.2 cm (range 0.5-7.2 
cm) and median tumor volume 22.2 cm3 (range 1.1-322). All patients with primary 
tumors, except one, had cirrhotic livers. In contrast, in the metastases group, only one 
patient had liver function impairment with signs of portal hypertension (cardial and 
esophageal varices). Probably, this was due to portal vein thrombosis developed after 
previous radiotherapy performed elsewhere because of other liver metastases.
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Table 1. HCC Patient characteristics
Patient
HCC
Cirrhosis
Child-Pugh 
grade
Vascular invasion Lesion
number
Lesion
size (cm)
Liver 
segment
Treatment
1 A Yes
(PVT)
1 3.5 6 3x12.5Gy
2 A Yes 1
2, 3
7.2
0.5, 0.5
2
2, 2
5x5Gy*
5x5Gy
3 A No 1 6.1 1 5x5Gy
4 A No 1 4.5 6 5x5Gy
5 B No 1, 2 1.6, 1.3 3, 6 3x12.5Gy
6 B Yes
(PVT)
1 4.5 7 3x10Gy
7 A No 1 2.2 7 3x12.5Gy
8 No No 1 6 8 3x12.5Gy
PVT : portal vein thrombosis. * Patient 2 developed 2 new lesions (2,3) in the same segment close to the initially 
treated lesion. Although there was not a relapse of the lesion 1 (still 5.6 cm diameter) there was a simultaneous re-
treatment with 5 x 5 Gy of the fi rst lesion.
Table 2. Liver metastases. Patient characteristics
Patient
Metastases
Primary
tumor
Lesion
number
Lesion
size (cm)
Liver segment Treatment
1 Colorectal 1 Microscopic rest 7 3x10Gy
2 Colorectal 1 4.0 4 3x12.5Gy
3 Colorectal 1, 2 3.7, 1.3 7, 7 3x12.5Gy
4 Lung 1, 2 1.5, 0.5 7, 7 3x12.5Gy
5 Colorectal 1
2, 3
2.7
1.6, 1.3
8
8, 8
3x12.5Gy
3x12.5Gy
6 Colorectal 1, 2, 3
4, 5
2.8, 2.0, 1.0
1.5, 1.6
4a, 4a, 4a
2, 3
3x10Gy
3x12.5Gy
7 Colorectal 1 2.3 1 3x12.5Gy
8 Breast 1, 2 , 3, 4 1.4, 1.2, 1.0, 2.1 4a, 6, 8, 8 3x12.5Gy
9 Colorectal 1, 2 3.9, 1.5 1, 8 3x12.5Gy
10 Colorectal 1 6.2 4a 3x12.5Gy
11 Colorectal 1, 2, 3 6, 3.9, 3.2 2, 4, 4 3x10Gy
12 Colorectal 1, 2 2.8, 0.7 1, 3 3x12.5Gy
13 Colorectal 1, 2 4.1, 0.8 7, 7 3x12.5Gy
14 Colorectal 1 2.4 1 3x12.5Gy
15 Carcinoid 1 3.2 4 3x12.5Gy
16 Colorectal 1 2.7 4 3x12.5Gy
17 Colorectal 1, 2 3.3, 1.0 1, 7 3x12.5Gy
Lesions 3-4 were very close to each other and considered as one target.
Dose-fractionation schemes
The dose was prescribed at the 65% isodose that surrounded the PTV. Patients with 
liver metastases, HCC without cirrhosis, and HCC < 4 cm and cirrhosis were mostly 
treated with 3 fractions of 12.5 Gy. Three patients with liver metastases have been 
treated with 3 fractions of 10 Gy. One patient because of the presence of only micro-
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scopic disease (after non-radical microscopic surgery), another patient because of the 
small bowel in the high dose area, and the third one because of the amount of normal 
liver involved in the high dose region. For patients with HCC ≥ 4 cm and cirrhosis, 
treatment consisted initially, for the fi rst 3 patients, on 5 fractions of 5 Gy (5 x 5 Gy). 
Because no grade 3-4 toxicity was observed but a local failure was evidenced in two of 
them very close after treatment (see below), retreatment was performed using 3 frac-
tions of 8 Gy without evidence of severe toxicity. These two patients were considered 
as a failure for the actuarial local control calculations. The dose was increased for the 
last patient to 3 fractions of 10 Gy. Treatment fractions were delivered every second 
day. Overall treatment time was 5-6 days for 3 fractions and 10 days for 5 fractions. 
Treatment preparation and execution
For SBRT patients were positioned in the Elekta Stereotactic Body Frame (SBF) (Elekta 
Oncology Systems, Stockholm, Sweden) with maximum tolerable abdominal compres-
sion to reduce respiratory tumor motion. All patients had a planning, an arterial and 
a venous contrast CT scan. The rim of contrast enhancement was taken as boundary 
of the clinical target volume (CTV) and was delineated on the arterial and venous 
contrast CT scans and summed to construct the defi nitive 3-D CTV. The tumor delin-
eations were reviewed by an experienced radiologist (S. M. Hussain/ S. Dwarkasing). 
Initially, the applied PTV margin was based on the Karolinska experience (5-10 mm) 
(12). Currently, implanted gold fi ducials and fl uoroscopy are used to assess residual 
tumor motion in all directions and margins are individualized.
Treatment plans (Fig. 1A and 1B) were generated with the Cadplan treatment plan-
ning system (Varian Oncology Systems, Palo Alto, CA) with 4-10 coplanar and nonco-
planar beams. The following normal tissue constraints were used (13): for normal liver 
D33% < 21 Gy, D50% < 15 Gy, for bowel, duodenum, stomach and esophagus D5cc < 21 
Gy, for spinal cord Dmax < 15 Gy and for kidney D33% < 15 Gy.
The treatments were delivered with a Siemens Primus linear accelerator (Siemens 
Oncology Systems, Concord, CA). Just prior to each treatment fraction a contrast CT 
scan was acquired to assess tumor motion and bony anatomy displacements in the SBF. 
Also, electronic portal images were used to exclude movements of the patient (bony 
anatomy) in the SBF during transport from the CT scanner to the linear accelerator 
and to verify applied SBF setup corrections, in case of detected tumor displacements 
in the SBF at the CT scanner.
Follow-up and defi nition of local failure
All patients had a multiphase gadolinium enhanced liver MRI scan, a liver function 
test, and tumor marker assessment between 4 and 6 weeks prior to treatment plan-
ning, and at 1, 2, 3 months after treatment and periodically every 3 months during 
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Fig. 1A. T2-weighted MR image shows one hyperin-
tense metastasis in segment 7 with a small satellite 
lesion (arrow).
Fig. 1B. CT-planning showing the delineations cor-
responding to the two liver metastases in segment 7, 
both included in one target, the GTV arterial and ve-
nous phase, the organs at risk (liver, bowel and spinal 
cord), the PTV surrounded by the 65% isodose and 
the 33% isodose.
Fig. 1C. T2-weighted MR image shows complete 
remission with morphological parenchymal changes 
due to radiation hepatitis 21 months after treatment.
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the fi rst 2 years, and every 6 months thereafter. The tumor size was evaluated on 
a MRI axial reconstruction and the volumes with the contrast CT scan delineations. 
Local failure was defi ned as increase in tumor size and/or steady increase of tumor 
marker values above normal, without evidence of new intra- or extrahepatic lesions at 
any point during the follow-up. Median follow-up for local control was 12.9 months 
(range 0.5-31).
Toxicity evaluation 
Acute toxicity was evaluated during the fi rst 3 months after treatment with the Com-
mon Toxicity Criteria (CTC), version 2.0 of the National Cancer Institute. The SOMA/ 
LENT grading system was used to score the late toxicity. Radiation induced liver 
disease (RILD) was defi ned as, anicteric ascites and elevation of alkaline phosphatase 
levels to at least two fold increase above the pretreatment values in absence of tumor 
progression, classic (14), or hepatic toxicity grade 3 or higher according to the CTC 
also in absence of tumor progression, non-classic (15,16).
Statistics 
To assess local control and survival, Kaplan-Meier curves were generated with SPSS, 
version 11.5. 
This retrospectively analyzed phase I-II study was approved by the Ethical Commis-
sion of Erasmus MC and all patients have given their written consent.
RESULTS
Local control 
Local failure was observed in four out of 45 lesions in four patients (2 HCC, 2 metas-
tases). One HCC patient presented a steady increase of AFP 7 months after treatment 
without increase in tumor size but with an active rest lesion on a PET scan. The other 
HCC patient showed an in fi eld regrowth after initial decrease of lesion size and 
elevated AFP 4 months posttreatment. These two patients were treated with 5 x 5 
Gy. Two metastases patients presented an in fi eld regrowth after an initial complete 
remission with an increase of the CEA level at 31 and 21 months after treatment. Both 
patients were treated with 3 x 12.5 Gy. An example to illustrate a complete remission 
is shown in Figure 1C. 
The actuarial one and two year local control rates were 94% and 82% for the 
whole group and 100% and 86% for the metastases group, respectively (Fig. 2). For 
the HCC the one year and twenty-two months local control probability were 75% 
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(maximum follow-up of a HCC in local control is 22 months). Crude local control rates 
for liver metastases and HCC were 94% and 82%, respectively. 
Actuarial overall survival rates at one and two years (Fig. 3) were 82% and 54% for 
the whole group; 85% and 62% for the metastases group, and 75% and 40% for 
HCC patients.
Fig. 2. Actuarial local control function. The curve 
corresponding to the whole group and liver metas-
tases drops at the end until zero because the patient 
with largest follow-up (31 months) presented a local 
failure.
Fig. 3. Actuarial survival function.
Toxicity 
Changes in the liver function parameters grade 1-2, were present in all the patients 
except one (grade 0) in the fi rst 3 months after treatment. Within the HCC group, one 
episode of RILD classic and non-classic was observed. Two weeks after treatment, a 
Child B patient presented hepatic toxicity grade 4 with signs of decompensated portal 
hypertension, bleeding from esophageal varices, and fever from a urinary infection. 
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The patient died within the fi rst month after treatment and the toxicity was evaluated 
as grade 5. Two patients presented ascites grade 2 with less than two fold increased 
alkaline phosphatase and hepatic toxicity (CTC) less than grade 3, responding well to 
temporary diuretic medication. No late toxicity was found. In the metastases group, 
two episodes of RILD non-classic were found in the fi rst 3 months after treatment. 
Two patients presented an elevation of gamma glutamyl transpherase (GGT) grade 
3. In one case the increase was isolated, without any symptom or parallel increase of 
other liver function parameters. In the other, an increase of the other liver parameters 
and asthenia (both grade 2) was observed. One patient developed asthenia grade 3 
with hepatic toxicity grade 2 during the fi rst month after treatment and recovered 
spontaneously during the second month. Also, one episode of ascites grade 2 with 
less than two times increase of alkaline phosphatase was observed in one patient after 
being treated three times with radiotherapy (last two in our center) and previously 
with surgery. Late toxicity could also be present in this patient because of the develop-
ment of a portal hypertension syndrome with one melena episode that was evaluated 
as SOMA grade 3. No esophagus, stomach, bowel or kidney toxicity was found. 
DISCUSSION
Local control whole group 
Our results, with local control rates of 94% and 82% at 1 and 2 years, respectively, 
are in accordance with those published from similar studies in the literature (Table 3) 
(9, 13, 17-20). The better local control compared to Wulf et al. (13) and Shefter et al. 
(19) can perhaps be explained by the higher doses used in the present study. Herfarth 
et al., in a recent publication (21), have reported results of 70 patients, 35 of the fi rst 
phase I/II trial (18) (4 primary tumors, 51 metastases) and 35 treated after the trial was 
closed (51 metastases, mainly colorectal). Actuarial local control rates were 66% at 18 
months and 60% at 2 years. The lower results in comparison with those from the fi rst 
35 patients were due to a poor local control rate of the colorectal metastases group 
(see metastases section).
Separate comparisons for HCC and metastases are diffi cult to perform, as most 
studies don’t make this separation in their analysis.
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Table 3. Comparison of local control and survival between studies using hypofractionated radiotherapy
Author Lesions
(p)/(lm)
Dose-
fractionation scheme
(prescription isodose)
Median
follow-up
moths
(%) Actuarial
local control 
1, 2 years
(%) Actuarial
survival 
1, 2 years
Blomgren 18/20 1-3x5-15Gy(p) (65%)
2-4x10-20Gy (lm) (65%)
Mean 12
Mean 9.6
NRP*
NRP*
NRP#
NRP#
Wulf 1/23 3x10Gy (65%) 9 76, 61 71, 43
Herfath 4/102 1x20-26Gy (80%) Mean 14.9 66¶, 60 76, 55
Wada 6/5 3x15Gy (90-100%) 19.3 NRP, 71.2 NRP, NRP
Schefter 1/15 3x7-10Gy (80-90%) 10.1 47(at10.1m), NRP NRP, NRP
Fuss 1/17 3-6x6-12Gy (NRP) 6.5 94, NRC 80, NRC
Kavanagh 0/NRPμ 1x20Gy (80-90%) 100, 93% NRP, NRP
Present 
study
11/34 3-5x5-12.5Gy (p) (65%)
3x10-12.5Gy (lm) (65%)
12.9 94, 82 (wg)
75, 75§
100, 86
82, 54 (wg)
75, 40
85, 62
(p): primary tumors (HCC/ cholangiocarcinoma). (lm): liver metatases. (wg): whole group. 
NRP: not reported. NRC: not reached.
*Crude local control at last follow-up: 100% for HCC and 95% for liver metastases. #Mean survival 13.4m for HCC and 
mean 17.8m for liver metastases. ¶ At 18 months. μ 36 treated patients § At 22 months.
Local control HCC 
Blomgren et al. (9) reported a crude local control at last follow-up (median 12 months) 
of 100%. Our result of 80% crude local control at one year is lower but this needs 
further consideration. All tumors in the present study treated with 3 x 12.5 Gy stayed 
in local control. The difference with the results from Blomgren et al. is due to our 
poor local control achieved for large tumors with cirrhosis, probably because of the 
too low total dose delivered (5 x 5 Gy). A clear dose effect relationship for HCC has 
been established in the literature by Dawson et al. and Park et al. (10, 22); eventually 
the combination with a large size, as demonstrated by Wada et al. (20) could have 
infl uenced the low local control rate.
Local control metastases 
Kavanagh et al. observed local control rates of 100% and 93% at 1 and 2 years, in 
36 liver metastases patients treated with 3 fractions of 20 Gy (pers. comm.). Probably, 
the delivered higher doses have decreased the local failure rate in comparison with 
our study. Herfarth et al. (21) performed a separate analysis considering only the 
metastases patients. They observed that colorectal metastases presented a poorer lo-
cal control than those with other histology (45% vs. 91% after 18 months), especially 
for those treated previously with systemic chemotherapy, that could have selected 
radioresistant cells. We observed better local control rates even with a population 
including mainly colorectal metastases (27 of 34 lesions). It might be possible that 
our patients were treated less with chemotherapy and this could explain the observed 
difference.
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Toxicity whole group 
Comparison with other groups is diffi cult because of different or not mentioned scor-
ing systems used to report toxicity. However, the data from the literature (9,13,18-20) 
seem to suggest that published toxicity for the whole group is lower than in our study. 
Toxicity HCC
Cheng et al. and Jiang et al. (15, 16) have demonstrated that patients with cirrhosis 
Child-Pugh grade B have a high risk to develop toxicity (RILD). As well, Cheng et al. 
conclude that hepatitis B virus (HBV) was also associated with higher susceptibility for 
RILD but the mean liver dose and the V30Gy (percentage of normal liver volume that 
received a radiation dose > 30 Gy) were not statistical signifi cantly correlated. This 
is in agreement with our experience. We had two patients with Child-Pugh B that 
also carried HBV. One who developed tumor progression and could therefore not be 
evaluated for toxicity. The other patient presented fever two weeks after treatment, 
due to an infection, with signs of increased portal hypertension and RILD, progressing 
to liver failure and death. Although it is known that in cirrhotic patients a liver decom-
pensation can be associated with infections, possibly the radiation induced edema 
increased the portal pressure and the subsequent bleeding contributed to deteriorate 
the unstable liver function. This patient had a V30Gy of 6% and the mean and the 
median liver dose were also low, 8.6 and 3.4 Gy (converted to 2 Gy per fraction with 
/ = 2). HCC with cirrhosis Child-Pugh A and patients without cirrhosis, regardless of 
size, didn’t show any toxicity grade ≥ 3. Possibly, the absence of severe liver function 
impairment makes them less susceptible to develop complications.
Toxicity metastases
Within the metastases group, we observed grade 3 hepatic toxicity in two patients 
based on an increased GGT. The published phase I trial from the Colorado and Indiana 
groups (23) showed that for metastases, escalating the dose until 60 Gy delivered in 
3 fractions was possible, without reaching the maximum tolerated dose for grade 3-4 
toxicity. In this study, at least 35% of normal liver, or 700 ml, estimating a normal 
liver volume of 2000 ml, had to receive a total dose less than 15 Gy. Analysis of the 
dose-volume histogram of the two patients with hepatic toxicity showed that 53% 
and 60% of the normal liver received 15 Gy or less corresponding to 638 and 639 ml, 
respectively. The fi rst patient was treated because of two targets and the second one 
had a small liver volume after previous operations. The patient with asthenia grade 3 
was treated with chemotherapy and resection prior to radiotherapy what could have 
infl uenced the development of more constitutional symptoms.
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CONCLUSIONS
SBRT was feasible, with an acceptable toxicity and encouraging local control, es-
pecially for liver metastases. More studies including larger numbers of patients are 
necessary to verify these results and to fi nd optimal dose-fractionation schemes for 
HCC patients with cirrhotic livers. If patients with Child-Pugh B are considered for 
treatment extreme caution should be used because of the high risk to develop toxicity. 
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ABSTRACT
Purpose: Stereotactic body radiation therapy (SBRT) provides a high local control rate 
for primary and metastatic liver tumors. The aim of this study is to assess the impact 
of this treatment on the patient’s quality of life. This is the fi rst report on quality of life 
associated to liver SBRT.
Methods and Materials: From October 2002 until March 2007, a total of 28 patients 
not suitable for other local treatments and with a Karnofsky performance status of at 
least 80%, were entered in a Phase I-II study of SBRT for liver tumors. Quality of life 
was a secondary end point. Two generic quality of life instruments were investigated, 
EuroQol-5D (EQ-5D) and EuroQoL-Visual Analogue Scale (EQ-5D VAS) , in addition, a 
disease-specifi c questionnaire, the European Organization for Research and Treatment 
of Cancer Core Quality of Life Questionnaire (EORTC QLQ C-30). The points of mea-
surement were directly before, and 1, 3 and 6 months after treatment. Mean scores 
and SDs were calculated. Statistical analysis was performed using paired-samples 
t-test and Student t-test.
Results: The calculated EQ-5D index, EQ-5D VAS, and QLQ c-30 global health status 
showed that the mean quality of life of the patient group was not signifi cantly infl u-
enced by the treatment with SBRT; if anything, a tendency towards improvement was 
found.
Conclusions: Stereotactic body radiation therapy combines a high local control rate, 
by delivering a high dose per fraction, with no signifi cant change in quality of life. 
Multicenter studies including larger numbers of patients are recommended and under 
development.
Acknowledgments: The authors thank Elly Stolk, Ph.D., and Rob A. de Man, M.D., 
Ph.D., for their valuable contributions.
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INTRODUCTION
Clinical studies on the effect of stereotactic body radiation therapy (SBRT) included 
local control, survival and toxicity. However, this outcome did not measure the infl u-
ence of the treatment on the quality of life of patients. Quality of life is an important 
health parameter and provides useful information to clinicians and patients about 
the impact of a treatment on the health status. SBRT is an emerging local treatment 
option for patients with intrahepatic malignancies not eligible for surgery or radiofre-
quency ablation (RFA). Several reports showed high local control rates with acceptable 
toxicity associated to this treatment (1-4). To achieve these favorable local response 
rates, high radiation doses in a small number of fractions are delivered. Application 
of high-precision patient positioning (rigid) and control of the respiratory liver motion 
(5-7) may have an impact on the patient’s well being during the treatment and on the 
subsequent quality-of-life evaluation.
The aim of the present study is to assess, prospectively, the impact of SBRT on the 
quality of life of patients with primary and metastatic liver tumors. To our knowledge, 
this is the fi rst report of quality of life associated to hypofractionated stereotactic liver 
treatments.
METHODS AND MATERIALS
Patients characteristics
From October 2002 to March 2007, a total 28 patients were entered in a phase I-II 
study on SBRT for liver tumors, approved by the Ethical Commission of Erasmus MC 
and in accordance with the Declaration of Helsinki. All patients gave their written 
consent. Results on local control, survival, and toxicity were reported recently (3). 
Quality-of-life assessment was a secondary endpoint of this study. Patients included 
were those with a diagnosis of liver metastases or hepatocellular carcinoma (HCC), 
who were not candidates for other local treatments, including surgery and RFA. Liver 
cirrhosis assessment was suggested by the case history (hepatitis virus B infection, 
hepatitis virus C infection and alcohol abuse) and was performed by studying the 
typical aspects defi ning cirrhosis on computed tomography and magnetic resonance 
imaging. Portal hypertension splenomegaly was determined by means of imaging 
techniques and the presence of esophageal varices by gastroscopy. Patients with a 
diagnosis of liver metastases had no typical aspects of cirrhosis on computed tomog-
raphy or magnetic resonance imaging. Karnofsky index was at least 80%. Patient and 
tumor characteristics are presented in Table 1.
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Table 1. Patient and tumor characteristics
Gender
 Male
 Female
23
5
Median age (years) 68 (37-81)
Patient diagnosis
 Liver metastases
 HCC
19
9
Primary site of metastases
 Colorectal
 Lung
 Breast
17
1
1
Cirrhosis (all within HCC group)
 Child- Pugh grade A
 Child- Pugh grade B
6
2
Previous treatments
 Surgery
 Ethanol injection
 RFA
 Chemotherapy
12
2
6
10
No. of lesions treated
 Liver metastases
 HCC
38
11
Median lesion size (cm) 3.0 (0.5-7)
Median lesion volume (cc) 54.5 (1.03-322.5)
HCC = hepatocellular carcinoma.
Treatment 
Details on tumor delineation, patient setup, methodology used for liver motion con-
trol, treatment planning, treatment accuracy, margins and treatment delivery, have 
been previously published (3, 7). Briefl y, patients were positioned in the Elekta ste-
reotactic body frame (Elekta Oncology Systems, Stockholm, Sweden) with maximum 
tolerable abdominal compression to decrease respiratory tumor motion for planning 
and treatment purposes. Patients with metastases, HCC without cirrhosis, and HCC 
less than 4 cm with cirrhosis were treated mostly with 3 x 12.5 Gy. Patients with HCC 
of 4 cm or larger and cirrhosis received 5 x 5 or 3 x 10 Gy. The prescription isodose 
was 65%. Treatment plans were generated with the Cadplan treatment planning 
system (Varian Oncology Systems, Palo Alto, CA) with a median of eight coplanar and 
noncoplanar beams (range 4-10 beams). Acute toxicity was evaluated during the fi rst 
3 months after treatment by using the Common Toxicity Criteria, version 2.0, of the 
National Cancer Institute. The Subjective, Objective, Management and Analytic Scales/
Late Effects of Normal Tissue (SOMA/LENT) grading system was used to score the late 
toxicity (3).
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Quality of life instruments 
The effect of SBRT on quality of life was studied by using two generic quality of life 
instruments, the EuroQol-5D (EQ-5D) and the EuroQoL-visual analogue scale (EQ-5D 
VAS), in addition to a disease-specifi c questionnaire, the European Organization for 
Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ 
C-30). Patients completed these three instruments at home using a validated Dutch 
translation. Measurements obtained with these questionnaires were meant to de-
scribe what the patient has experienced as a result of the treatment intervention, and 
to supplement traditional measures of health (3, 8).
The EQ-5D is a standardized instrument for use as a measure of health outcome 
applicable to a wide range of health conditions and treatments. It was developed by 
a multidisciplinary international group (the EuroQoL Group), (9, 10) as a generic ques-
tionnaire comprising fi ve domains: mobility, self-care, usual activities, pain/discomfort 
and anxiety/depression. Each question has three response categories: 1, indicates 
no problems; 2, some or moderate problems; and 3, inability or extreme problems. 
Responses to the items are combined to give a descriptive health-related quality-of-life 
state (11). The EQ-5D VAS is a sixth item added to the other EQ-5D domains to give 
a global evaluation of the health state using a VAS ranging from 0 (worst imaginable 
health state) to 100 (best imaginable health state) (12). The QLQ C-30 (version 1.0) 
is a reliable and validated instrument developed by the EORTC to evaluate the quality 
of life of patients with cancer in multicultural clinical research settings (13). It is a 
30-item questionnaire composed of multi-item scales and single items. It incorporates 
fi ve functional scales (physical, role, cognitive, emotional and social), three symptom 
scales (fatigue, pain and nausea and vomiting) and a global health and quality-of-life 
scale. The remaining single items assess additional symptoms commonly reported 
by patients with cancer (dyspnea, appetite loss, sleep disturbance constipation and 
diarrhea) as well as the perceived fi nancial impact of the disease and treatment. All 
scales and single items have a score range of 0-100. A high score for a functional scale 
represents a high/healthy level of functioning. A high score for the global health status 
represents a high quality of life. However, a high score for a symptom item represents 
a high level of symptomatology/problems.
Time points for assessing quality of life 
Published reports on liver SBRT showed that treatment-related effects were expected 
mainly within the fi rst 6 months after treatment (1-4, 14). Based on this observa-
tion, our main goal was to get most of the quality-of-life questionnaires completed 
and returned within 1 month before treatment (baseline), and at 1, 3 and 6 months 
after treatment. Additional information on quality-of-life data was registered every 3 
months during the fi rst year and every 6 months thereafter. Patients with evidence 
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of disease progression during follow-up were referred to other departments, and 
no further quality-of-life information was requested to prevent bias caused by other 
treatment modalities or the effect of the disease. 
For those patients treated more than once, we assumed that the treatment was not 
fi nalized until the last course was completed. This means that the selected measure 
times started before the fi rst treatment (baseline) and were resumed, according to the 
schedule, after the last treatment was delivered.
Statistical analysis 
Mean scores and SDs were calculated for the EQ-5D index, the EQ-5D VAS and all 
the EORTC scales. Comparisons with the EQ-5D index obtained from a general Dutch 
population and with the QLQ C-30 global health status from a general Norwegian 
population were performed. Statistical analysis was carried out with the statistical 
program SPSS version 12.0 (SPSS Inc., Chicago, IL). Paired-samples t-test and Student 
t-test were carried out. The level of statistical signifi cance was considered p < 0.05 for 
all the calculations.
RESULTS 
Data collection 
Twenty-eight treated patients were considered candidates to be included in this study. 
One patient with residence outside The Netherlands was excluded because of lack of 
adequate follow-up. In addition, 1 patient did not want to participate in the study. 
From the remaining 26 patients, 25 pretreatment forms were submitted. One ques-
tionnaire was missing. 
One month after treatment, 1 patient died (possibly treatment-related death) and 
1 patient did not return the form (missing). From 25 patients available for follow-up, 
24 forms were returned. 
At 3 months, 1 patient was transferred to another department because of disease 
progression, 2 patients did not respond because they were on holidays outside the 
country and they had not taken the questionnaires, and 5 forms were missing. From 
24 patients available for follow-up, 17 forms were returned for analysis.
At 6 months, 4 more patients were referred to other departments because of dis-
ease progression. The remaining 20 patients available for data submission completed 
and returned the instruments. 
After 6 months, the number of collected forms decreased rapidly. At 9 months, only 
eight forms were returned and two were missing. At 12 months, seven forms were 
collected. At 18, 24 and 30 months only three, three and two forms were returned, 
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respectively. At these times, most patients underwent chemotherapy because of 
disease progression.
In all cases, when the patient responded, all three questionnaires, the EQ-5D, EQ-5D 
VAS and EORTC QLQ C-30, were completed.
Quality of life analysis 
An overview of the quality-of-life domains at different time is listed in Table 2.
Mean values corresponding to the EQ-5D index, EQ-VAS score and C-30 global 
health status increased after treatment compared with the baseline (Fig. 1). How-
ever, no statistical signifi cance was evidenced when paired t-tests between baseline 
values and those obtained at 1, 3 and 6 months after treatment were performed. 
Mean values corresponding to symptom-specifi c domains seemed to increase after 
treatment (presence of more intense symptoms). Except for fatigue at 1 month (p = 
0.004), paired t-tests comparing functional and symptom items at baseline and after 
treatment did not show a statistical signifi cant difference.
Table 2. Mean values and standard deviations of EQ-5D health state index, EQ-5D VAS score, EORTC QLQ C-30 global 
health status and C-30 functional and symptoms scales
Baseline 
(n = 25)
+1 Month 
(n = 24)
+3 Month 
(n = 17)
+6 Month 
(n = 20)
Mean SD Mean SD p Mean SD p Mean SD p
EQ-5D health state index 0.79 0.21 0.81 0.17 0.85 0.80 0.17 0.84 0.81 0.24 0.69
EQ-5D VAS score 69.2 16.1 70.8 15.0 1.00 72.9 16.5 0.54 71.3 16.8 0.71
C-30 global health status 50.3 21.0 55.2 17.0 0.51 60.8 20.1 0.12 55.0 19.4 0.58
Functional scales
 Physical Functioning 72.0 20.0 70.0 21.3 0.18 70.6 18.9 0.38 75.0 18.2 0.66
 Role Functioning 68.0 31.9 68.8 28.8 1.00 73.5 25.7 0.08 77.5 25.5 0.66
 Emotional Functioning 74.6 22.0 77.4 20.6 0.40 78.9 22.6 0.29 82.9 15.9 0.19
 Cognitive Functioning 80.0 25.0 81.3 19.8 1.00 87.3 23.2 0.72 86.7 15.9 0.17
 Social Functioning 82.0 26.3 84.0 25.3 0.60 81.4 23.5 0.77 90.0 13.7 0.81
Symptom scale/item
 Fatigue 26.2 22.6 34.3 24.1 <0.01 28.1 17.6 0.53 29.4 19.5 0.20
 Nausea & Vomiting 5.3 12.5 4.2 8.9 0.78 4.9 9.8 0.77 7.5 12.7 1.00
 Pain 16.0 21.2 16.7 22.5 1.00 16.7 20.6 0.54 20.6 28.8 0.61
 Dyspnea 16.0 23.8 22.2 27.2 0.26 21.6 23.4 0.18 20.0 22.7 1.00
 Insomnia 20.0 27.2 20.9 30.8 0.66 25.6 32.4 0.49 25.2 32.4 0.37
 Appetite loss 8.0 17.4 8.3 17.7 0.57 15.7 26.6 0.06 13.3 22.7 0.18
 Constipation 5.3 20.8 6.9 19.6 0.71 3.9 16.2 0.33 8.3 23.9 1.00
 Diarrhea 9.3 18.1 4.2 11.3 0.66 3.9 11.1 0.58 6.7 13.7 1.00
 Financial diffi culties 6.7 19.2 6.9 24.0 1.00 9.8 28.3 1.00 5.0 16.3 1.00
All p-values were obtained using paired-samples t-test between baseline and 1, 3 and 6 months after treatment. 
Abbreviations: EQ-5D=EuroQoL-5D, EQ-5D VAS=EuroQoL Visual Analogue Scale, EORTC QLQ C-30=European 
Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire.
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Comparison with baseline values of a general population 
A statistically signifi cant difference (p = 0.014) was found by using Student t-test be-
tween the baseline EQ-5D index from our group and the EQ-5D of a general Dutch 
population group between 60-69 years (mean 0.86 years; SD 0.20 years; E.A. Stolk, 
personal communication, January 2007). Comparison with the EORTC global health 
status obtained from a general Norwegian population group between 60-69 years, 
(mean age for male group 73.6 years; for female group, 69.4 years) and assuming the 
same SD, (not reported) also showed a statistically signifi cant difference (p < 0.001) (15).
Fig. 1. Mean values of the (a) EuroQoL (EQ-5D) 
health state index, (b) EuroQoL-Visual Analogue 
Scale (EQ-5D VAS) score, and (c) European 
Organization for Research and Treatment of Cancer 
Core Quality-of-Life Questionnaire (EORTC QLQ 
C-30) global health status.
60
70
80
90
100
C-30 global health status
al
u
e
(c)
0
10
20
30
40
50
0 1 3 6
Time [month]
M
ea
n
 v
60
70
80
90
100
EQ-D5  VAS score
al
ue
(b)
0
10
20
30
40
50
0 1 3 6
Time [month]
M
ea
n
 
v
a
0.6
0.7
0.8
0.9
1.0
EQ-D5 health state index
al
ue
(a)
0.0
0.1
0.2
0.3
0.4
0.5
0 1 3 6
Time [month]
M
ea
n
 v
a
Alejandra Mendez bw.indd   40 03-02-11   13:23
41
Quality of life after SBRT for liver tumors
3
DISCUSSION
Stereotactic body radiation therapy applied to primary and metastatic liver tumors 
showed a high local control rate. Our aim was to investigate whether this positive 
effect was achieved without quality-of-life impairment. Our results show that quality 
of life did not deteriorate despite the delivered high-fraction doses. 
Based on the health-related quality-of-life conceptual model proposed by Wilson 
and Cleary (8), we analyzed quality of life at several levels: general health perceptions, 
functioning and symptoms. General health perceptions were measured by using the 
EQ-5D health state index, EQ-5D VAS score and QLQ C-30 global health status index. 
They constitute our primary result. Although mean values obtained at baseline were 
lower than in the general population, they remained quite stable after treatment. 
Functional and symptom status were evaluated by using the EORTC C-30 functional 
and symptom domains, respectively. Mean values corresponding to functional domains 
were also stable after treatment compared with baseline. Mean values corresponding 
to symptom domains, showed slightly higher scores after treatment, although only 
fatigue at 1 month resulted in a signifi cant difference compared with baseline. This 
fact did not affect the subjective evaluation of quality of life. 
The purpose of the study was specifi cally to evaluate the impact of the treatment on 
the quality of life of the patients by means of quality-of-life questionnaires. We believe 
we obtained high response rate; 96% before treatment, and 96%, 70% and 100% 
at 1, 3 and 6 months after treatment respectively. One has to realize that patients 
were only studied in case of response or stable disease. That is, if disease progression 
was detected, patients were excluded from further analysis to avoid bias from other 
treatments or from the effect of the disease. 
To test robustness of our results, we compared our fi ndings with the literature. 
Clinical studies that have analyzed the impact of local liver treatments on quality of 
life are scarce. Moreover, the fact that different groups were administrated different 
instruments to measure quality of life, which makes comparison almost impossible. 
We compared the EQ-5D health state index and EORTC QLQ C-30 global health 
status between available data obtained from general population samples and our pa-
tient group. The aim was to investigate whether the baseline scores of our group were 
similar to those of the general population. As expected, EQ-5D scores in our group 
were signifi cantly lower than those obtained in a sample from the general Dutch 
population. In addition, comparison with the EORTC QLQ C-30 global health status 
obtained from a general Norwegian population (15) showed the same result. These 
observations possibly refl ect the impact of disease and treatments on the patient’s life 
regardless of a readjustment process (discussed next).
Langehoff et al. (16) analyzed quality of life after surgical treatment in three groups 
of patients with colorectal liver metastases. The fi rst group underwent the planned 
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resection of metastases or was treated with local tumor ablation if resection alone was 
not possible. The second group was found to have inoperable disease at laparotomy 
and underwent exploratory laparotomy only (no resection or local ablative therapy 
with curative intent was possible). The third group consisted of patients referred 
for surgery, but judged to have inoperable disease and therefore not scheduled for 
surgery. This last group was included as a control group. The same three quality-of-life 
instruments as applied in our study were administered; the EQ-5D, the EQ-5D VAS; 
and the EORTC QLQ C-30. Quality-of-life data before the intervention and at 2 weeks, 
3 and 6 months after that were reported. Although the EQ-5D baseline is more or less 
similar to our group, they found, contrary to us, EORTC scales similar to norm scores 
obtained from the general population. They suggested that these high scores might 
be caused by a reframing process. Reframing (17) is described as an integral part of 
patient’s adaptation to disease and treatment and is related to the patient’s ability to 
adjust to the limitations of disease and treatment. A potential explanation may be that 
regardless of a reframing process, the outcome refl ected that the patients referred 
for SBRT had already experienced an extensive treatment armamentarium, including 
(several) liver resections or RFA procedures and different chemotherapy schemes. An 
evident decrease of global health status and functional scales was found by Langehoff 
et al. (16), together with an increase in symptoms scales at 2 weeks after the opera-
tion for Groups 1 and 2 that returned to baseline at 3 months for Group 1 and at 6 
months for Group 2. Our data did not show a decrease in quality of life directly after 
treatment. Within the symptoms domain, fatigue was the only item that showed 
a statistical signifi cant difference (at 1 month), and might be associated with the 
treatment effect. Contrary to Group 3 of Langehoff et al. (16), with decreased scores 
at 6 months in absence of treatment, remarkably, after SBRT, we found no signifi cant 
decrease of quality-of-life domains 6 months after treatment. This suggests that SBRT, 
as surgery or RFA, may help to maintain the patient’s quality of life. 
Wietzke-Braun et al. (18) analyzed to the impact of ultrasound-guided laser intersti-
tial thermotherapy on quality of life in patients with unresectable liver metastases from 
primary colorectal cancer. The administered questionnaire was the EORTC QLQ C-30, 
and the times for evaluation were before treatment, and at 1 week, 1 month and 6 
months after the intervention. In agreement with our fi ndings, they also reported 
no signifi cant change in functional scales or global health status after treatment. A 
signifi cant increase in symptoms regarding pain was detected. They suggest that this 
might be related to the local incision and insertion of the catheter. Contrary to the 
signifi cant increase in fatigue only during the fi rst month after SBRT, increased pain 
after ultrasound-guided laser interstitial thermotherapy reached statistical signifi cance 
not only 1 week after treatment but also 6 months after that. 
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Our study presents the main limitation of the small number of patients. Therefore, 
the positive fi ndings reported here need confi rmation in a larger study. The North 
European Liver Tumor Group is preparing a Phase III randomized trial for liver metas-
tases, comparing RFA with SBRT. Data will be collected from 300 patients to analyze 
recurrence-free survival as a primary end point, and quality of life as a secondary end 
point.
CONCLUSIONS 
Data from this study show that apart from the high local control rate, SBRT was also 
associated with a constant quality of life, maintaining the pretreatment level in the 6 
months after the treatment period. Obviously, despite the delivered high doses, there 
is no posttreatment decrease in quality of life related to unavoidable exposure of 
healthy tissues. Possibly, the obtained local control resulting from the high doses may 
even prevent a decrease in quality of life. Currently, in Europe, a large study is being 
prepared that will provide data to validate these fi ndings.
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ABSTRACT
Purpose: To investigate whether computer-optimized fully noncoplanar beam setups 
may improve treatment plans for the stereotactic treatment of liver tumors.
Methods: An algorithm for automated beam orientation and weight selection (Cycle) 
was extended for noncoplanar stereotactic treatments. For 8 liver patients previously 
treated in our clinic using a prescription isodose of 65%, Cycle was used to generate 
noncoplanar and coplanar plans with the highest achievable minimum planning target 
volume (PTV) dose for the clinically delivered isocenter and mean liver doses, while 
not violating the clinically applied hard planning constraints. The clinical, and the 
optimized coplanar and noncoplanar plans were compared, with respect to DPTV,99%, 
the dose received by 99% of the PTV, the PTV generalized equivalent uniform dose 
(gEUD) and the compliance with the clinical constraints.
Results: For each patient, the ratio between DPTV,99% and Disoc, and the gEUD-5 and 
gEUD-20 values of the optimized noncoplanar plan were higher than for the clini-
cal plan with an average increase of respectively 18.8% (range 7.8-24.0%), 6.4 Gy 
(range 3.4-11.8 Gy) and 10.3 Gy (range 6.7-12.5). DPTV,99%/Disoc, gEUD-5 and gEUD-20 of 
the optimized noncoplanar plan was always higher than for the optimized coplanar 
plan with an average increase of respectively 4.5% (range 0.2-9.7%), 2.7 Gy (range 
0.6-9.7 Gy) and 3.4 Gy (range 0.6-9.9 Gy). All plans were within the imposed hard 
constraints. On average, the organs at risk were better spared with the optimized 
noncoplanar plan than with the optimized coplanar plan and the clinical plan.
Conclusions: The use of automatically generated, fully noncoplanar beam setups 
results in plans that are favorable compared to coplanar techniques. Because of the 
automation, we found that the planning workload can be decreased from 1 to 2 days 
to 1 to 2 h.
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INTRODUCTION
The number of patients with metastatic or primary liver tumors treated with external 
beam radiotherapy is increasing. Often the patients treated with this modality can 
not be operated on or treated with another local modality such as radio frequency 
ablation, or percutaneous ethanol injection therapy.
In some institutes, hypofractionated stereotactic radiotherapy is used (1-6), applying 
a stereotactic body frame (SBF) with abdominal compression for reduction of respira-
tory tumor motion. In 2002, using the Elekta SBF (Elekta AB, Stockholm, Sweden), this 
type of treatment has been started in our clinic, for metastatic and hepatocellular car-
cinoma (HCC) lesions. Patients accepted for treatment cannot be treated with surgery 
or other local treatments such as radiofrequency ablation or percutaneous ethanol 
injection. The maximum allowed diameter of the lesion is 6 cm. With the patient po-
sitioned in the SBF, arterial and venous contrast computed tomography (CT) scans are 
made for tumor defi nition as well as a planning CT scan for contouring of the organs 
at risk (OAR). Delineated tumors in the arterial and venous CT scans are summed 
to construct the defi nitive clinical target volume (CTV). To determine the required 
CTV-to-planning target volume (PTV) margin, the residual respiratory tumor motion, is 
assessed with fl uoroscopy at a conventional simulator using implanted fi ducials. The 
patients are treated mostly with three fractions of 10-12.5 Gy (depending on disease 
type and tumor size), prescribed at the 65% isodose, that closely surrounds the PTV. 
This inhomogeneous dose concept is based on the work of Lax et al. (7). They showed 
that for a constant dose at the periphery of the PTV, a 50% increase in the target 
center dose can be obtained, compared with a homogeneous dose concept, without 
a substantial increase of dose to the normal tissue. To irradiate liver tumors, most 
clinics use three-dimensional conformal therapy with a set of manually selected beam 
directions and forward treatment planning. Generally, coplanar beam directions are 
used, whereas in some cases, noncoplanar setups have been applied (8, 9). Thomas 
et al. (10) investigated for a group of patients whether manually chosen noncoplanar 
beam setups (i.e., with noncoplanar and coplanar directions) are more favorable for 
intensity-modulated radiation therapy treatment of liver tumors. They concluded 
that for the group of patients with a tumor close to an OAR, the noncoplanar setup 
improved the treatment plan. For the other patients, the plans with a noncoplanar 
beam setup were as good as those with a seven beam equidistant coplanar setup or 
as those using the beam setup of the clinical plan.
In this article, we have investigated the benefi t of noncoplanar beam setups for 
hypofractionated, stereotactic treatment of liver tumors, using automated beam direc-
tion selection from a large set of coplanar and noncoplanar input directions. For this 
purpose, our in-house developed beam direction selection algorithm, Cycle (11,12), 
was extended for handling of stereotactic (inhomogeneous) PTV dose distributions 
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including an option for beam shape optimization. For 8 liver patients previously 
treated in our clinic using a prescription isodose of 65%, Cycle was used to generate 
noncoplanar and coplanar plans with the highest achievable minimum PTV doses 
for the clinically delivered isocenter and mean liver doses. The clinically applied hard 
planning constraints were also used for the automated plan generation. The clinical, 
and the optimized coplanar and noncoplanar plans were compared, with respect to 
DPTV,99%, the dose received by 99% of the PTV, the PTV generalized equivalent uniform 
dose (gEUD), and the distance from the applied constraint levels.
METHODS AND MATERIALS
Description of liver plans
In clinical practice, the liver treatment plans were designed by a dosimetrist using 
forward trial-and-error planning. Both coplanar and noncoplanar beams (open or 
wedged) could be selected. For practical reasons not more than 10 different directions 
were allowed in a plan. The dose (3 x 10 Gy or 3 x 12.5 Gy) was prescribed to the 65% 
isodose level. The clinical treatment plans for the 8 patients in this study consisted 
of fi ve to nine coplanar beams. In addition, in Case 8, three noncoplanar beams 
were used. The workload of the manual treatment plan generation was 1-2 days. 
The delineated OAR with their clinical constraints are summarized in Table 1. Because 
the tumor location was heterogeneous among the patient group, not all OARs were 
always relevant for all patients.
Short description of Cycle algorithm
The general principles of the Cycle algorithm for automated beam orientation and 
weight selection have been described in detail by Woudstra et al. (11-14). Here, a 
summary is given with the focus on some extensions. The algorithm aims at generating 
a treatment plan with the prescribed tumor dose (isocenter), whereas not exceeding 
the imposed hard constraints. The algorithm starts with an empty plan. Sequentially 
(Fig. 1), new beams are added to the plan by selection from a large set of potential 
input directions based on a score function. 
The selection of beams stops, if the selected beams result in a plan that can be 
scaled to the prescribed PTV dose without violation of any constraint level (the plan 
generation is successful), or if no more beams can be added without violation of one 
of the constraints, or if the number of allowed directions is reached. In the last 2 cases 
a new plan generation is started with automatically adjusted penalty factors in the 
score function (11, 12).
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Table 1. Applied constraints in the iterative optimization of the minimum PTV dose
Structure Constraint Constraint parameter
PTV DPTV,rel <D
t
P
o
T
l
V,rel (n) N.A.
Normal liver Dmean <Dmean,clinical N.A.
Normal liver D50% <15 Gy D50%/15
Normal liver D33% <21 Gy D33%/21
Spinal cord Dmax <15 Gy Dmax /15
Bowel, duodenum, stomach,  esophagus, 
heart, aorta. D5CC <21 Gy D5CC /21
Kidney’s D33% <15 Gy D33%/15
R1 Dmax N.A.
R2 Dmax <20 Gy N.A.
NA = not applicable; PTV = planning target volume.
DtP
o
T
l
V,rel (n) is the applied constraint level in iteration n on the relative PTV dose inhomogeneity. In the iterative proce-
dure, DPTV,rel is minimized by repeated runs of Cycle with decreasing values of D
t
P
o
T
l
V,rel (see text). Da% indicates that a% 
of the volume receives a dose of at least Da% and DaCC indicates that a CC receives a dose of at least DaCC. Structures 
R1 and R2 and the maximum tolerated dose in R1 are defi ned in the text. The constraint parameters, Cj , for OAR con-
straints, j, are required for calculation of the DIP (eq. 2).
Strictly speaking, by itself, Cycle is not an optimization algorithm; its aim is genera-
tion of an acceptable plan (i.e. attaining the prescribed dose without exceeding the 
constraints). The score function is used to build such an acceptable plan and not to 
defi ne and generate the “best” plan. However, in an iterative loop, the algorithm 
may indeed be used to optimize a plan parameter (14). In this study, such a procedure 
was used to maximize the minimum PTV dose (see below, section “Maximizing the 
minimum PTV dose”).
Beam shape optimization
Usually beam direction optimization for three-dimensional conformal radiotherapy is 
performed with a fi xed fi eld/segment shape for each of the beam directions in the 
initial set (11-15). Often the beams’ eye view (BEV) projection of the target and an 
additional margin for the penumbra is used for the determination of the fi eld shape 
(11, 16).
In this article, we study stereotactic treatments with highly inhomogeneous PTV 
dose distributions that are very sensitive to the selected beam sizes. Because each 
selected beam passes through the liver, each beam contributes to the mean liver 
dose. The contribution of an individual beam is approximately proportional to the 
liver volume incorporated by that beam, which is proportional to the area of the fi eld 
of that beam. On average, the fi elds have a diameter in the order of about 5 cm. An 
addition or subtraction of a margin of 0.5 cm from the fi eld shape, may therefore 
increase/reduce the fi eld area by about 30%. 
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Therefore an extension was made to the Cycle algorithm, to enable optimization 
of the fi eld shape for each input direction. First, an initial fi eld shape is made, based 
on the BEV projection of the target (without penumbra margin). With this shape the 
beam weight is optimized. After that, the algorithm tries to further increase the score 
by expanding or reducing the margin in small steps (2 mm), in four independent 
perpendicular directions (+x, -x, +y, -y). Each step requires a recalculation of the off-
axis dose distribution of the beam. A beam direction can be selected multiple times. 
In general, each time it will be selected with a different shape and weight; therefore, 
a plan can have multiple segments per beam direction.
Fig. 1. Schematic diagram of the Cycle algorithm.
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Input beam directions
For the coplanar plans, Cycle used 72 input beam directions evenly distributed in the 
axial plane. For the noncoplanar plans, the input beam directions were distributed 
in separate sets of 36 or 72 beam directions. The beam directions in each set have 
the same angle with the axial plane, , and they are evenly distributed with an equal 
separation in  (see Fig. 2). For  = 0 (i.e. the axial plane), the same 72 input beam 
directions were used as for the coplanar plans. For sets with other  values (i.e. for the 
noncoplanar input beams), 36 input beam directions were used.
Increments in  of 10° were used. The upper and lower  were determined manu-
ally, using the BEV (see Table 2). The set of noncoplanar beam directions with the up 
or low is the set with the highest |  | for which none of the beams enters through 
the upper (cranial) or lower (caudal) CT slice, i.e. up and low were determined by 
the cranialcaudal extent of the CT scan. If the separation between up or low and the 
nearest set of input directions was ≥ 5o, an extra set of input beam directions was 
defi ned for up or low.
Fig. 2. Patient coordinate system and angles ,  for defi nition of the input noncoplanar beam directions. O is the 
isocenter and, z is the cranialcaudal direction of the patient. OP is an example of a beam direction.  is the angle of 
the xy-plane (axial plane) with OP.
Maximizing the minimum PTV dose
In the procedure to maximize the minimum PTV dose, the isocenter dose in the clinical 
plan was used as the prescribed dose for the PTV, DpP
r
T
e
V. The minimum PTV dose was 
then optimized in an iterative procedure, by minimizing the relative PTV dose inho-
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mogeneity, DPTV,rel = (Disoc/DPTV,min)/Disoc (see Table 1). In fi rst instance, for the constraint 
on the relative PTV dose inhomogeneity, DtP
o
T
l
V,rel, the level of the clinical plan was used 
(35%). If Cycle succeeded in generating a plan, the DtP
o
T
l
V,rel level was decreased with 
a step of 1%. This was repeated until plan generation was no longer successful (i.e. 
DpP
r
T
e
V could not be attained without a constraint violation). As mentioned previously, 
the allowed maximum number of beam directions in the clinical plans was 10. To 
generate clinically acceptable plans, and for a straightforward comparison with the 
manually created clinical plans, the allowed number of beam orientations in the Cycle 
plans was also limited to 10. Apart from the DtP
o
T
l
V,rel constraint, generation of plans 
was always subject to the constraints in Table 1. To end up with a probability on liver 
complication for the optimized plans equal to or lower than the clinical plan, the 
mean dose constraint on the normal liver volume (i.e. the entire liver minus the CTV) 
was set to the clinically achieved mean normal liver dose value (17).
For Cases 5-7, the clinical plan had a relatively low prescribed dose (Table 2). For 
these patients, in a second step, an attempt was made to escalate the absolute iso-
center PTV dose. This was again done in an iterative way, by increasing the prescribed 
isocenter dose while keeping the relative PTV dose inhomogeneity constraint, DtP
o
T
l
V,rel, 
constant. For DtP
o
T
l
V,rel, the value used in the last iteration of the optimization procedure 
for the minimum PTV dose (see previous) was used. The iterative procedure was 
stopped if further isocenter dose increase was prevented by a constraint violation.
Nonorgan-specifi c regions in normal tissue
Apart from organ based constraints (e.g. for the kidneys) for automated plan genera-
tion, two other regions were defi ned in the normal tissue by expansions of the PTV 
(expansion 1 is the PTV plus a 2.0 cm margin, expansion 2 is the PTV plus a 5.0 cm 
margin). Region R1, was all tissue outside expansion 1 and inside expansion 2. Region 
R2, was all tissue outside expansion 2. For each region a maximum dose constraint was 
imposed (Table 1). The constraint on R1 aims at conformality of the dose distribution 
Table 2. Patient characteristics, the prescribed dose for the clinical plans (65 % isodose), the αlow and αup defi ning the 
sets of input beam directions and, the number of input directions for the noncoplanar plan
Case VPTV (CC) Vliver (CC)
Prescription
dose (Gy) low up
No. of input 
beam directions
1 74.5 1271.0 3 x12.5 -30 5 216
2 113.4 1228.0 3 x12.5 -30 19 252
3 121.4 768.3 3 x12.5 -30 10 216
4 105.9 1869.0 3 x12.5 -30 5 216
5 211.8 1601.0 3 x10.0 -20 10 180
6 46.9 1011.0 3 x10.0 -30 20 252
7 111.2 985.9 5 x 5.0 -9 9 144
8 264.7 1632.0 3 x12.5 -28 10 216
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to the target volume, whereas the constraint on R2 avoids hot spots far away from the 
target volume. The value for the constraint on R1 was chosen 5-10 Gy lower than the 
minimum PTV dose level. The exact value of this constraint was chosen in such a way, 
that it was not a limiting constraint for maximizing the minimum PTV dose. If, during 
the optimization process, a plan generation failed because of violating this constraint, 
the constraint level was relaxed. For R2, a maximum dose constraint of 20 Gy was used 
for each patient (Table 1).
Plan comparison
As described previously, the main goal of the iterative use of Cycle was to maximize 
the minimum dose in the PTV, whereas not exceeding the clinically delivered mean 
liver dose and without violation of the other clinical constraints. In this study, the 
ratio between DPTV,99%, the minimum dose received by 99% of the PTV, and Disoc, the 
isocenter dose, was used for evaluation of the plans. Also the gEUD of the PTV was 
evaluated using the following formula (18),
a/N
i
a
ia DN
gEUD
1
1
1 

 
  
(1)
With N the number of do se points, Di. The a parameter (a < 0) represents the aggres-
siveness of the tumor, with an increased aggressiveness for more negative  values. 
In this study the gEUD was calculated with  values of -5 and -20 (10). Potentially, an 
improved DPTV,99% value for a constant mean normal liver dose could be accomplished 
at the cost of a closer approach of other constraint levels. To evaluate this, the distance 
from ideal plan (DIP), as defi ned by Woudstra et al. (12), was calculated for each plan.


 M
j
j
M
C
DIP
1
2
 
(2)
In which Cj are the OAR constraint parameters as mentioned in Table 1. M is the 
number of OAR constraints. For the optimized plans the maximum doses delivered to 
regions R1 and R2 in the normal tissue were also evaluated. For plan evaluation, the 
maximum dose in R1 was subtracted from DPTV,99%. This value represents the minimum 
dose gradient between the PTV and region R1.
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RESULTS
PTV: Optimized noncoplanar plan vs. clinical plan
The results for the PTV of the clinical, the coplanar and the noncoplanar plans are 
summarized in Tables 3 and 4. 
For each case, DPTV,99%/Disoc and the gEUD-5 and gEUD-20 values were substantially 
higher for the optimized noncoplanar plan than for the clinical plan. For DPTV,99%/Disoc 
the average increase was 18.8% (range 7.8 - 24.0%). The average increase for gEUD-5 
and gEUD-20 was respectively 6.4 Gy (range 3.4 - 11.8 Gy) and 10.3 Gy (range 6.7 - 
12.5 Gy) (Table 4). In Fig. 3, the dose-volume histograms of the normal liver volume 
and the PTV are plotted for Case 2. The increase in PTV dose is clearly visible. The high 
dose volume in the normal liver is slightly higher for the optimized plans, because of 
the increase in minimum PTV dose. This increase is however compensated by a smaller 
normal liver volume receiving a low dose, to end up with the same mean liver dose.
Table 3. DPTV,99%/Disoc for the clinical and the optimized coplanar and noncoplanar plans
Case Clinical Coplanar Noncoplanar
1 61.0% 82.3% 85.0%
2 63.2% 76.6% 83.3%
3 70.4% 84.1% 88.4%
4 67.7% 80.0% 87.2%
5 69.1% 87.4% 87.6%
6 83,1% 87.9% 90.9%
7 61.6% 74.6% 84.3%
8 70.5% 88.6% 90.1%
Mean 68.3% 82.7% 87.2%
Table 4. gEUD-5 and gEUD-20 values for the clinical and the optimized coplanar and noncoplanar plans
a = -5 a = -20
Case Clinical Coplanar Noncoplanar Clinical Coplanar Noncoplanar
1 48.2 51.9 53.1 43.7 50.4 52.1
2 46.5 50.6 53.1 40.5 48.1 52.0
3 49.1 54.3 55.7 43.7 53.2 55.2
4 48.9 52.4 54.4 43.5 50.9 53.9
5 39.9 46.9 47.5 35.8 46.3 46.9
6 44.4 46.6 56.2 43.4 46.0 55.9
7 31.1 32.9 34.5 27.0 31.0 33.7
8 49.4 51.5 54.3 43.5 50.2 53.5
Mean 44.7 48.4 51.1 40.1 47.0 50.4
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PTV: Coplanar vs. noncoplanar plan
In each case, the optimized noncoplanar plan was better than the optimized coplanar 
plan (Tables 3 and 4). The increase in DPTV,99%/Disoc was on average 4.5% (range 0.2 
- 9.7%). The average increase in gEUD-5 and gEUD-20 was respectively 2.7 Gy (range 
0.6 - 9.7 Gy) and 3.4 Gy (range 0.6 - 9.9 Gy) (Table 4). The total number of selected 
beam directions was 10 for all of the optimized plans except for 1 case which had 
nine directions for the noncoplanar plan. The average ratio between the number of 
segments and the number of beam directions in a plan was 2.0 (range 1.4 - 3.1) for 
the noncoplanar plans, and 2.7 (range 1.8 - 3.9) for the coplanar plans. 
Resulting dose distributions of Case 2 are shown in Fig. 4. Because of the close 
proximity of the heart, the aorta and the esophagus to the target as well as the 
eccentric position of the target in the liver, this case was rather complicated. In the 
slice 2 cm cranial from the isocenter slice, the increased dose homogeneity for the 
noncoplanar plan can be seen from the 45-Gy isodose, which is at the edge of the PTV 
for the noncoplanar plan (Fig. 4b) and inside the PTV for the coplanar plan (Fig. 4d).
PTV: dose escalation
For Cases 5-7, it was tried to escalate the isocenter dose with a constant PTV inho-
mogeneity as described previously. Escalation succeeded for the Cases 5 and 6. The 
increase in Disoc with respect to the clinical plan was 3.5 Gy and 2.9 Gy for respectively 
the noncoplanar plan and the coplanar plan of Case 5 and 11.0 Gy and 1.5 Gy for, 
respectively, the noncoplanar plan and the coplanar plan of Case 6. For the nonco-
planar plan of Case 6, the iteration procedure for minimization of the relative PTV 
dose inhomogeneity (fi rst step, see section Maximizing the minimum PTV dose) was 
Fig. 3. DVHs of the dose distribu-
tions in the PTV and the normal 
liver for the clinical plan and the 
optimized noncoplanar and copla-
nar plans of Case 2.
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stopped after the 90% PTV dose homogeneity level was reached, which was not the 
highest achievable homogeneity level. This explains the large increase in Disoc. The liver 
volume in Case 7 was relatively small (Table 2), and the PTV was situated in the center 
of the liver. For Cases 5 and 6, the PTV was located at the edge of the liver. In the 
latter cases, beams could be selected that involved a rather small volume of normal 
liver, whereas in Case 7 this was not possible.
(a)
(b)
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Normal tissues
As aimed for, all optimized plans delivered the clinically prescribed isocenter dose 
with the same mean liver dose as for the clinical plan, without violation of the normal 
Fig. 4. Dose distributions for Case 2 for the noncoplanar plan (a and b) and the coplanar plan (c and d) for the iso-
center slice (a and c) and a slice 2-cm cranial from the isocenter (b and d). The dashed lines are the projections of the 
beam axis of the noncoplanar beam directions in the axial slices, the solid lines are the beam axis of the coplanar 
beam directions. The labels indicate the angle, α, between the beam axis and the axial slices.
(c)
(d)
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tissue constraints. The mean liver dose constraint was the limiting constraint for 
further increase of the minimum PTV dose in each case. In Table 5, the clinical plan 
and the optimized coplanar and noncoplanar plans are compared with respect to the 
maximum doses in the regions R1 and R2. In 6 of the 8 cases, the optimized coplanar 
plans have a higher difference between DPTV,99% and the maximum dose in R1, than 
the clinical plans. In 7 of the 8 cases, the optimized noncoplanar plans have a higher 
DPTV,99% - DR1,max, than the optimized coplanar plans. In 6 of the 8 cases the maximum 
dose in R2 is lower for the optimized coplanar plan than for the clinical plan. In 6 of 
the 8 cases the maximum dose in R2 is lower for the noncoplanar plan than for the 
coplanar plan. 
The DIP was calculated for each case as explained in the Methods section. The 
average DIP of the optimized noncoplanar plans was both lower than the DIP for 
the clinical plans, and lower than the DIP for the optimized coplanar plans (Table 
6). Tables 3-6 illustrate that noncoplanar beam setups allow the highest minimum 
PTV doses, and gEUD-5 and gEUD-20 values, while avoiding most approaching OAR 
constraint levels.
Table 5. Comparison between the noncoplanar, coplanar, and the clinical plans with respect to the maximum dose 
delivered to the normal tissue regions R1 and R2
DPTV,99% - DR1,max DR2,max
Case Clinical Coplanar Noncoplanar Clinical Coplanar Noncoplanar
1 8.2 6.3 14.7 19.6 19.2 17.9
2 3.4 4.5 11.8 22.1 20.0 15.6
3 1.1 21.1 22.3 21.3 18.8 17.3
4 5.3 20.3 18.1 26.3 17.8 19.1
5 3.3 7.6 8.6 12.2 19.8 19.2
6 8.5 12.5 16.4 21.4 19.2 19.0
7 6.0 5.3 7.7 13.1 13.3 14.3
8 -0.1 1.5 8.0 24.7 19.9 18.7
Table 6. Distance from ideal plan for the optimized coplanar and noncoplanar plans and the clinical plan
Case Noncoplanar Coplanar Clinical
1 0.025 0.115 0.094
2 0.224 0.264 0.254
3 0.257 0.292 0.293
4 0.223 0.255 0.205
5 0.169 0.160 0.161
6 0.159 0.213 0.246
7 0.175 0.137 0.155
8 0.240 0.243 0.231
Mean 0.184 0.210 0.205
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DISCUSSION
Automatically optimized beam selection for the stereotactic treatment of liver tumors 
results in increased DPTV,99% values compared to the clinical plan, for the same isocenter 
and mean normal liver doses, without violation of the clinical constraints, and even 
avoiding best approaching these constraints. For noncoplanar beam setups the im-
provement in DPTV,99% is higher than for coplanar beam setups. Automatically selected 
noncoplanar beam setups also have a higher dose gradient between the PTV and the 
normal tissue region R1 than the automatically selected coplanar beam setups, and on 
average, a lower DIP than the coplanar plans.
A plan produced by Cycle has an optimal number of beams, in the sense that Cycle 
stops adding beams when the prescribed dose is attained. In this study, the number 
of selected beam directions was dependent on how strict the relative PTV dose inho-
mogeneity constraint,DtP
o
T
l
V,rel, was set. In the fi rst steps of the iterative optimization 
procedure, when DtP
o
T
l
V,rel was not very strict (see Maximizing the minimum PTV dose), 
the number of selected beam directions was usually lower than 10. With the DtP
o
T
l
V,rel 
constraint becoming more strict, the number of selected directions increased, until 
the maximum number of allowed beams per plan (i.e., 10) was reached. Unlike the 
number of beam directions, the number of segments was not limited in the plan op-
timization. It was demonstrated that in a coplanar plan the average number of beam 
segments per beam orientation was substantially higher than for the noncoplanar 
plan (2.7 vs. 2.0). 
Except for 1 case, the number of beam directions for the plans generated by Cycle 
was 10. With regard to the required treatment time, this might be a high number, 
especially for noncoplanar cases because of the need for couch rotation. However, the 
treatment is given in only three fractions. So the relative effect of the high number of 
beams on the treatment time is much less than for a treatment with a conventional 
fractionation scheme. For most cases all selected directions are noncoplanar direc-
tions. Cases 5 and 8 had respectively six and seven noncoplanar directions in the 
beam setup of the noncoplanar plan. These two cases had the lowest improvement 
in DPTV,99%, (Table 3).
Thomas et al. (10) also investigated the use of noncoplanar beams for treatment 
of liver tumors, comparing three intensity-modulated radition therapy plans, each 
with a different beam setup. One setup contained noncoplanar directions, one setup 
used the directions applied in the clinical plan, and one setup used seven equidistant 
coplanar directions. They saw that the noncoplanar beam setup was only favorable in 
cases where the PTV incorporated another OAR besides the liver. In our study we see 
a clear advantage of applying noncoplanar directions in the beam setup for each case. 
A reason for these different observations might be that in our study the noncoplanar 
beam directions are computer optimized for each individual patient, which is not the 
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case in the study by Thomas et al. Moreover, in our study relatively small tumors are 
considered with small CTV-PTV margins, resulting from the abdominal compression, 
treated with stereotactic (inhomogeneous) PTV dose distributions.The maximum cal-
culation time for a plan with Cycle (allowing 10 restarts with adjusted penalty factors) 
on a workstation with an Intel Xeon 3.2 GHz processor was 2 h for a noncoplanar 
plan. For coplanar planning this calculation time was reduced by a factor of three.
In this study, we have assumed that the probability of liver complications is cor-
related with the mean normal liver dose, as found by Dawson et al. (17). Recently, 
Cheng et al. (19) showed for the treatment of primary tumors, that for hepatitis B 
virus carriers or Child Pugh grade B, this probability might be more correlated with the 
high dose delivered to the normal liver. Separate analysis would be required to assess 
the advantage of noncoplanar beam setups for these cases.
For all patients, the tumor was located in the upper part of the set of CT slices. 
Therefore, for 6/8 patients, up was not larger than 10° (Table 2), so only one set 
of noncoplanar directions entering the patient from the cranial direction could be 
defi ned. Despite the small angles between these noncoplanar directions and the axial 
plane, the noncoplanar plans are better than the coplanar plans for these 6 patients. 
A larger improvement may be expected if a larger part of the patient in the cranial 
direction is scanned.
Here, we have investigated the use of computer-optimized noncoplanar beam 
setups to improve the PTV dose distribution for liver tumors treated with stereotac-
tic radiotherapy. It was decided to aim at an increase in the minimum PTV dose in 
order to better approach the homogeneous PTV dose distribution in conventional 
radiotherapy. Cycle would also have allowed escalation of the isocenter dose while 
keeping the dose inhomogeneity constant, or escalation of the PTV gEUD. The choice 
to focus on elevation of the minimum PTV dose is in line with recent fi ndings of Wulf 
et al. (20) who found that in stereotactic treatment of lung tumors the dose at the 
PTV margin was the only signifi cant variable for local control. Integration of Cycle in 
the commercial treatment planning system XIO (CMS, Inc., St. Louis, MO) is being 
investigated.
CONCLUSIONS
The use of automatically optimized noncoplanar beam setups for stereotactic treat-
ment of liver tumors results in treatment plans with improved PTV coverage and 
reduced dose delivery to healthy tissues. Compared with manual forward planning, 
the planning time can be reduced from 1-2 days to 2 h at maximum.
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ABSTRACT
Purpose: To assess day-to-day differences between planned and delivered target 
volume (TV) and organs-at-risk (OAR) dose distributions in liver stereotactic body ra-
diation therapy (SBRT), and to investigate the dosimetric impact of setup corrections.
Methods and Materials: For 14 patients previously treated with SBRT, the planning CT 
scan and three treatment scans (one for each fraction) were included in this study. For 
each treatment scan, two dose distributions were calculated: one using the planned 
setup for the body frame (no correction), and one using the clinically applied (cor-
rected) setup derived from measured tumor displacements. Per scan, the two dose 
distributions were mutually compared, and the clinically delivered distribution was 
compared with planning. Doses were recalculated in equivalent 2-Gy fraction doses. 
Statistical analysis was performed with the linear mixed model.
Results: With setup corrections, the mean loss in TV coverage relative to planning 
was 1.7%, compared to 6.8% without corrections. For calculated equivalent uniform 
doses, these fi gures were 2.3% and 15.5%, respectively. As for the TV, mean devia-
tions of delivered OAR doses from planning were small (between -0.4 and +0.3 Gy), 
but the spread was much larger for the OARs. In contrast to the TV, the mean impact 
of setup corrections on realized OAR doses was close to zero, with large positive and 
negative exceptions.
Conclusions: Daily correction of the treatment setup is required to obtain adequate TV 
coverage. Because of day-to-day patient anatomy changes, large deviations in OAR 
doses from planning did occur. On average, setup corrections had no impact on these 
doses. Development of new procedures for image guidance and adaptive protocols 
is warranted.
Acknowledgments: The authors thank Evert Woudstra, Ph.D., Jeroen B. van de Kamer 
Ph.D., and Koos Zwinderman Ph.D., for their valuable contributions.
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INTRODUCTION
Stereotactic body radiation therapy (SBRT) for liver tumors has demonstrated a high 
local control rate with an acceptable toxicity (1-5). Because large radiation doses are 
delivered in a few fractions, high precision is required in tumor volume defi nition, daily 
setup, and dose delivery to guarantee accurate targeting and low toxicity. Precision 
in dose delivery is affected by anatomical changes in the liver and organs at risk, such 
as variable fi lling, peristalsis, cardiac, and (residual) respiratory motion (6, 7). Day-
to-day changes in the liver position may impair target coverage in SBRT, as reported 
by several groups (5, 8-10). Therefore, the tumor position is commonly verifi ed with 
CT-guided treatment procedures to adjust, if necessary, the treatment setup before 
dose delivery (10). Methods to reduce, control, or track the respiratory motion have 
been developed, and are routinely used in SBRT (7, 11-14).
For SBRT of liver tumors, little is known about the impact of the daily varying, 
nonrigid patient anatomy and patient rotations on doses delivered to organs at risk 
(OARs). Even in image-guided treatments, optimal sparing of OARs according to the 
treatment plan is not guaranteed, because setup corrections are fully based on mea-
sured tumor displacements. Changes in OAR positions and shapes are not explicitly 
accounted for in these procedures. Moreover, also with corrected tumor setups, dif-
ferences in radiological path lengths between planning and treatment, resulting from 
patient anatomy variations or rotations, may jeopardize target dose distributions.
The purpose of this study is to determine day-to-day dose deviations in the target 
volume (TV) and OARs for SBRT of liver tumors, and to assess the impact of daily 
tumor setup corrections on these deviations. For a group of 14 patients, two dose 
distributions were retrospectively calculated for each of the three treatment scans: 
one using the planned setup for the body frame (no correction), and one using the 
clinically applied (corrected) setup. Per scan, the two dose distributions were mutually 
compared, and the clinically delivered distribution was also compared with the plan-
ning.
METHODS AND MATERIALS
Patients 
This study included 14 patients entered in a phase I-II study, with a total of 23 liver 
metastases, consecutively treated in our institution between April 2003 and Novem-
ber 2006 (3). The patients were discussed in a multidisciplinary liver tumor board, 
and were not considered eligible for other local treatments, including surgery (due 
to limited remnant or co-morbidity) or radiofrequency ablation (due to unfavorable 
location). Patient and tumor characteristics are presented in Table 1.
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Table 1. Demographics
Patient Gender Age (y) Primary
tumor
Tumor
number
Tumor size Tumor volume (cc) Liver 
segment
Liver
volume
1 Male 70 Colorectal 1, 2 3.9, 1.5 53.4, 14.3 1, 8 1162.3
2 Male 75 Colorectal 1 2.8 76.2 8 1469.7
3 Female 56 Lung 1, 2 1.5, 0.5 7.2 7, 7 1251.4
4 Male 81 Colorectal 1 6.2 112.7 4 1765.8
5 Male 70 Colorectal 1 2.3 26 1 1292.7
6 Male 44 Colorectal 1, 2 2.8, 0.7 53.8, 3.2 1, 3 2412.1
7 Male 70 Colorectal 1 4.7 183.5 4 2907.1
8 Male 53 Colorectal 1, 2 4.1, 0.8 32, 8.7 7, 7 1166.6
9 Male 79 Colorectal 1, 2, 3 4.9,3.7,1.2 84.9,58.4 8,6,6 2060.7
10 Female 63 Carcinoid 1 3.2 31.1 4 1095.1
11 Male 58 Colorectal 1 2.4 13.8 1 1690.3
12 Male 72 Colorectal 1, 2 3.3, 1.0 43.1, 12.2 1, 7 2190.3
13 Male 52 Colorectal 1, 2, 3 6, 3.9, 3.2 64.4, 17.4, 9.8 2, 4, 4 2343.3
14 Female 55 Colorectal 1 3.4 35.8 4 1647.8
* Due to the close proximity of the tumors, they were considered as one volume for treatment purposes.
Treatment preparation
During (planning) CT scan acquisitions and treatments, patients were positioned in 
a stereotactic body frame (SBF) (Elekta Instrument AB, Stockholm, Sweden) with 
abdominal compression to reduce respiratory tumor motion. A large-volume planning 
CT scan, and two contrast-enhanced CT scans in arterial and venous phases were 
acquired for treatment preparation. The planning CT was matched with the contrast 
CT scans by registering the SBF’s position indicators included in the sidewalls (10). The 
tumor was delineated in both contrast-enhanced CT scans, after which the contoured 
volumes were joined to construct the composite clinical target volume (CTV). For 
each patient an MRI scan was available to assist tumor delineations. The planning 
target volume (PTV) was constructed from the composite CTV, initially using margins 
adopted from the Karolinska experience (13). The margins were individualized once 
fi ducial markers were implanted in the patients’ livers, enabling measurement of 
residual breathing motion with a video fl uoroscopy system (7). OARs were delineated 
in the planning CT scan.
Treatment was planned in 3 fractions, prescribing 12.5 Gy per fraction on the 65% 
reference isodose surrounding the PTV (1 patient received 3 fractions of 10 Gy because 
of a limited liver volume). The PTV coverage aimed for was ≥95%. OAR constraints as 
used for treatment planning adopted from Wulf et al. (3, 15) are presented in Table 2. 
OAR and PTV constraints were carefully followed during the design of the treatment 
plan. However, violations were occasionally accepted if not all constraints could practi-
cally be met. Treatment plans were designed using the Cadplan treatment-planning 
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system (Varian Oncology Systems, Palo Alto, CA) using a median of 8 (range 4-10) 
coplanar and noncoplanar beams.
Table 2. Dose constraints for the OARs in absolute dose per fraction, and recalculated as EQD2
OAR Absolute dose (Gy) EQD2 (Gy)
Duodenum D5CC 7.0 13.4
Heart D5CC 7.0 14.8
Kidneys D33% 5.0 8.3
Liver D33% 7.0 14.0
Liver D50% 5.0 8.0
Esophagus D5CC 7.0 13.4
Spinal cord Dmax 5.0 8.8
Stomach D5CC 7.0 13.4
OAR = organ at risk; EQD2 = equivalent 2-Gy fraction.
Treatment execution
On each treatment day, prior to dose delivery, a contrast-enhanced CT scan was 
acquired to establish the position of the tumor in the SBF. In this so-called treatment 
CT the physician delineated the CTV (treatment CTV). The treatment CT was matched 
with the planning CT by registering the SBF position indicators as previously described, 
such that the treatment CTV could be projected on the planning CT. If the CTV ap-
peared to have moved from the CTV position in the planning CT scan, a treatment 
isocenter correction was derived to realign the CTV with the original treatment plan. 
The correction was determined by projecting the PTV and treatment CTV contours 
in three orthogonal planes to measure distances between the contours. The planned 
coordinates for SBF setup at the treatment unit were then updated to establish the 
correction (shift) in the treatment isocenter. Details of the treatment procedures have 
been described by Méndez Romero et al. (3) and Wunderink et al.(10).
Calculated dose distributions
For each treatment CT, two treatments were simulated by calculating their dose distri-
butions: one treatment using the planned body frame setup (Tp), and one treatment 
using the corrected setup (Tc), as delivered in clinical practice. The beam confi guration 
with respect to the treatment isocenter was copied from the treatment plan and was 
identical in both treatment confi gurations; for the corrected setup, the position of the 
treatment isocenter was displaced according to the measured tumor displacement. 
The two confi gurations Tp and Tc, and the planning confi guration, P, are schematically 
summarized in Figure 1. All calculations were performed with the planning system 
also used for plan design.
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Fig. 1. Schematic explanation of treatment confi gurations Tp and Tc. (a) Planning CT scan with a single beam. (b) 
Treatment scan with the isocenter according to planning (Tp setup), the beam partially misses the target. (c) The same 
treatment scan, but with a corrected isocenter and corresponding beam set-up (Tc set-up). Abbreviations: TV = target 
volume, OAR = organ at risk, ISO = treatment isocenter.
TV dose assessments and comparisons
To avoid effects of tumor delineation uncertainties, the TV in each treatment CT was 
a copy of the PTV in the corresponding planning CT. For corrected setups, PTVs were 
positioned in the treatment scans by applying a shift in accordance with the displaced 
treatment isocenter (previous paragraph). As a result, for each corrected setup, all 
beam projections encompassed the PTV as in the planning situation (Fig. 1). Observed 
differences in target doses between a corrected setup and planning are then attributed 
to anatomical differences in the healthy tissues surrounding the target (radiological 
path length differences), and to (small) uncertainties in the applied procedures.
Target dose distributions were evaluated using TV coverages (percentage of the TV 
within the 12.5-Gy isodose volume), and calculated generalized equivalent uniform 
dose values (gEUD) with volume parameters a = -5 and a = -10 (16-19). Because of 
the high similarity of conclusions to be drawn from the a = -5 and a = -10 analyses, 
results are only shown for a = -5. For patients with more than one lesion (Table 1), the 
analyses were performed for the composite TV.
OAR dose assessments and comparisons 
For each simulated dose distribution, the following OAR dose parameters, (as also 
used for plan design; see above), were evaluated: liver D33%, liver D50%, bowel, duo-
denum, stomach and esophagus D5cc, spinal cord Dmax, kidneys D33%, and heart D5cc. 
For the parameter assessments, OARs were additionally contoured in all treatment CT 
scans. Despite the limited span of some treatment CT scans, for the serial OARs, the 
relevant regions (exposed to the high doses) were always included. In most treatment 
CT scans the caudal aspect of the kidneys was not completely included, requiring 
the following procedure to establish the dose parameters for these parallel organs. 
After registering the kidneys in the planning and a treatment scan, the kidneys in 
the treatment scan were completed by adding missing contours from the planning 
scan. Because the missing contours were to be placed outside the original scanned 
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volume, the treatment CT was fi rst extended with additional slices that were copies 
of the most caudal slice. In a similar way, additional slices were added to the volume 
boundaries if required in the treatment simulation to obtain representative radiologi-
cal path lengths. 
For all analyses, OAR dose parameters were converted into equivalent 2-Gy fraction 
doses (EQD2), using:
)/(
)/(dDEQD 



22  
(1)
where EQD2 is the dose in 2-Gy fractions that is biologically equivalent to a total dose 
D given with a fraction size of d gray (20, 21). For liver we applied an / value of 3.0 
Gy; for stomach, duodenum and esophagus 3.5 Gy; for spinal cord 2.0 Gy; for heart 
2.5 Gy, and for kidneys 2.5 Gy (21). The OAR constraint doses used for planning and 
converted to EQD2 are presented in Table 2. In the remainder of this paper, OAR doses 
refer to EQD2 values.
Statistics
For the descriptive statistics, established dose parameters for P, Tp and Tc were handled 
as separate measurements to give an overview of the actual data. To test the differ-
ence of the dose parameters or the chance of falsely rejecting the null hypothesis, “no 
difference” (p value), the linear mixed model was used, and correlation was assumed 
between the observations. The linear mixed model was selected because it can prop-
erly account for correlation between repeated measurements. The level of statistical 
signifi cance was considered  = 0.05 for all tests. Statistical analyses were performed 
using SPSS software, version 16.0 (SPSS Inc., Chicago, IL).
RESULTS
Target volume
Distributions of measured tumor displacements in the 42 treatment fractions relative 
to planning were 2.1, 4.0, and 1.5 mm (1 SD), for the lateral, superior-inferior, and 
anterior-posterior directions, respectively. Figure 2a shows for all treatment fractions 
the length of the three-dimensional setup error and differences in target coverage 
with planning if no corrections would have occurred (Tp-P), and for the actual treat-
ment with setup corrections (Tc-P). Distances between corresponding Tc-P and Tp-P 
data points in Figure 2a represent improvements in TV coverage resulting from the 
performed CT-guided tumor setup corrections. The planned mean target coverage for 
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the 42 fractions was 97.2%. Without setup corrections this would have decreased 
by 6.8% to 90.4%. With the clinically applied CT guidance, the mean coverage was 
95.5%, a reduction of 1.7% compared to planning (Figs. 3a and 4a). Patients 3, 11, 
and 14 had mean tumor setup errors in the three fractions of 7.9, 5.5, and 5.0 mm, 
respectively. Without corrections this would have resulted in mean target coverage 
losses of 21.1%, 14.9%, and 12.0%, respectively. Due to applied corrections, the 
reductions were limited to 2.9%, 4.4%, and 2.2%. All 42 setup corrections, but 
1 resulted in improved target coverage. The difference between Tc and Tp for this 
exception was only -0.2Gy. Ninety-fi ve percent of treatment fractions had a realized 
coverage after correction (slightly) lower than or equal to the planned coverage (p = 
0.001, Table 3).
Fig. 2. Deviations in (a) TV cover-
age and (b) generalized equiva-
lent uniform dose (gEUD) (-5) 
from planning before (Tp-P) and 
after (Tc-P) tumor setup correc-
tions.
Alejandra Mendez bw.indd   70 04-02-11   15:05
71
Impact of daily setup corrections and anatomy variations in liver SBRT
5
Fig. 3. Summarized planning and treatment dose distribution parameters. Summaries for planning (P), corrected treat-
ment simulations (Tc), and noncorrected treatment simulations (Tp) for (a) the target volume, and (b) organs at risk.
Table 3. Probability (p) values resulting from a linear mixed model, comparing dose distribution parameters in the 
simulated actual treatments (with setup corrections) with corresponding planned parameters (Tc vs. P), and compar-
ing differences between setup correction and no correction (Tc vs. Tp)
Dose distribution parameter Tc vs. Tp (p) Tc vs. P (p)
Duodenum D5CC 0.478 0.087
Heart D5CC 0.313 0.464
Kidneys D33% 0.630 0.788
Liver D33% 0.952 0.023
Liver D50% 0.781 0.015
Esophagus D5CC 1.000 0.769
Spinal cord Dmax 0.090 0.377
Stomach D5CC 0.157 0.480
TV* coverage 0.002 0.001
*p < 0.05 
Without corrections, 45% of fractions would have had a TV coverage lower than 
95%. With the applied corrections this was reduced to 24% (Fig. 5a). In the absence 
of corrections, 31% of fractions would have suffered from a coverage reduction rela-
tive to planning of 10% or more. With corrections, coverage reductions larger than 
10% could be fully avoided. 
Figure 2b shows for individual fractions, drops in gEUD(-5) that would have resulted 
from treatment with uncorrected tumor setup errors (Tp-P), and reductions in these 
gEUD(-5) losses with the applied setup corrections (compare with Fig. 2a). The mean 
planned fraction gEUD(-5) was 15.6 Gy (10-90% percentile range: 13.1-17.0 Gy). 
Without corrections, the mean gEUD(-5) for treatment would have been reduced 
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by 15.5% relative to planning (10% and 90% percentile values: -59% and -2%); 
52% of fractions would have suffered from a calculated gEUD loss of 5% or more. 
Performed corrections limited the gEUD reductions to an average of –2.3% (10% and 
90% percentile values: -4% and 0%), with only 10% of fractions having a gEUD loss 
(slightly) larger than 5%.
Organs at risk
OAR dose distribution parameters for planning (P) and the noncorrected (Tp) and 
corrected (Tc) treatment simulations are summarized in Figure 3b. Figure 4b contains 
Tc-P and Tc-Tp summaries. p values are presented in Table 3 (see also Discussion). 
Mean increases in OAR doses during treatment, relative to planning, (positive mean 
values for Tc-P in Fig. 4b) were all below 0.3 Gy. However, notwithstanding applied 
corrections, for some treatment fractions there were substantial deviations from plan-
ning. For example, in Fraction 1, Patient 1 had a duodenum D5cc of 12.5 Gy, whereas 
the planning showed 1.3 Gy; in Fraction 1, Patient 6 had a heart dose of 22.7 Gy, 
whereas the planning indicated 12.1 Gy; and Patient 4 had a stomach dose of 15.4Gy 
in Fraction 3, compared with a planned dose of 8.8 Gy. On the other hand, there were 
also important decreases in realized OAR doses relative to planning. For example, 
Patient 1 had a planned stomach dose of 29.9 Gy, whereas doses of 6.8, 7.0 and 6.4 
Gy were calculated for the three treatment scans (with corrected tumor setup errors 
of 4, 10 and 0 mm, respectively).
For the various OARs, the numbers of fractions with constraint adherence and 
constraint violation in the planning (P) and treatment simulations (Tc and Tp) are 
Fig. 4. Changes in dose distribution parameters for (a) target volume (TV), and (b) organs at risk. Tc-P = differences 
between simulated actual treatment and planning; Tc-Tp = changes related to tumor setup corrections.
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presented in Figure 5b. It confi rms that the impact of setup corrections on OARs was 
not as consistent as for the TV (compare Tc and Tp in Fig. 5b). For 7 patients, all OARs 
were planned within the constraints. From these patients, 1 had constraint violations 
in both the Tc and Tp treatment simulations. From the 7 patients with constraint 
violations in the planning, 1 patient was fully within the constraints in Tc, although 
above constraints in Tp. 
The Tc-Tp data in Figure 4b show that for all OAR dose distribution parameters the 
mean impact of correction was between -0.4 and +0.3 Gy. However, also here there 
were important deviations in individual patient fractions, both positive and negative. 
For example, because of the applied tumor setup correction, the duodenum dose of 
patient 1 in Fraction 1 went down from 17.5 to 12.5 Gy (still far above the planned 
value of 1.3 Gy; see above), and in Fraction 2 it decreased from 9.6 to 3.3 Gy; for 
Patient 6, tumor setup correction in Fraction 2 resulted in an increase in heart dose 
from 15.8 to 19.2 Gy, compared to no correction. Both the residual deviations in 
OAR dose distribution parameters from planning after tumor setup corrections (Tc-P, 
Fig.6a), and the impact of CT guidance on parameter deviations (Tc-Tp, Fig. 6b) are 
independent of the magnitude of the corrected tumor setup error. The latter fi nding is 
in strong contrast with observations for the TV (compare with Figs. 2 and 6).
Fig. 5. Constraint violations. Percentage of fractions within and without the planning constraints for (a) the target 
volume (TV), and (b) the organs at risk for the treatment plans (P), corrected treatment simulations (Tc), and noncor-
rected treatment simulations (Tp).
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Fig. 6. Differences between realized organ-at-risk dose distribution parameters (applying corrections) and (a) planned 
parameters (Tc-P), and (b) parameters that would have occurred without corrections (Tc-Tp).
DISCUSSION
Setup corrections were of major importance for adequate TV irradiation, especially in 
fractions with detected large tumor setup errors (Figs. 2a, 2b, 4a, and 5a). However, 
95% of treatment fractions had a realized coverage after correction (slightly) lower 
than or equal to the planned coverage (p = 0.001, mean deviation –1.7%). In addition 
realized gEUD values were on average lower than planned (-2.3%). With the high 
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planned target coverages (97.2% on average), for most points in the target edge, the 
planned dose is higher than or equal to the prescribed 12.5 Gy, and an increase here 
in dose relative to planning does not impact the TV coverage parameter. For these 
points, the parameter is only sensitive to negative dose deviations that may yield a 
drop in coverage. An increase in coverage compared to planning can only occur with 
enhanced treatment doses in the low percentage of points with a planned dose lower 
than 12.5 Gy. As a consequence, deviations of treatment dose distributions relative to 
planning are most likely to result in a TV coverage reduction, as was also observed in 
practice (above). By its nature, gEUD(-5) is most sensitive to dose reductions in the TV, 
yielding lower values. Consequently, when positive and negative target dose devia-
tions are equally distributed during treatments, treatment gEUD(-5) values are mostly 
lower than planned. This might explain the observed mean gEUD(-5) loss of 2.3%. 
As explained in Methods and Materials, differences from planning in the calculated 
realized target dose distributions cannot be attributed to tumor delineation variations. 
On the other hand, radiological path length differences between the planning and 
treatment CT scans may explain the differences. Additionally, we have found that the 
procedures for positioning beams around the TV in treatment CT scans may intro-
duce errors of up to 1 mm, resulting in some extra dosimetrical uncertainty. Hence, 
the observed mean differences in TV coverage and gEUD(-5) between planning and 
treatment of -1.7% and -2.3%, respectively, are upper limits for the mean impact of 
radiological path length variations on these parameters, originating from day-to-day, 
non-rigid patient anatomy variations or rotations.Obviously, the impact of radiological 
path length variations on TV dose delivery was much smaller than the impact of setup 
errors, if not corrected (Figs. 2a and 2b).
As presented in Results, for all OAR dose distribution parameters, the mean differ-
ence between correction (Tc) and nocorrection (Tp) was within –0.4 and +0.3 Gy. For 
the Liver D33% and D50%, the mean differences between actual treatment and planning 
(Tc-P) were –0.6 and –0.3 Gy, respectively, and during treatment these parameters 
were signifi cantly lower than planned (Table 3). No explanation has been found for 
this benefi t.
Reporting on clinically observed toxicity was not specifi cally the aim of this study. 
Results of 11 of the 14 patients have been previously reported (3). In the other 3 
patients, we did not fi nd any toxicity of Grade 3, 4 or 5. Although occasionally high 
doses above OAR constraints were delivered, in none of the 14 patients, severe toxic-
ity, such as perforation, cardiac insuffi ciency or neurological symptoms, observed. 
Many OAR dose-volume histograms showed a tail towards the high doses, suggesting 
that only a small volume was irradiated with high dose. Locations of hot spots within 
OARs may also change every treatment day owing to day-to-day variations in OARs’ 
positions and shapes.
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The PTV margins in our clinical protocol for SBRT of liver patients presume treatment 
with daily CT guidance (10). In this study we have found that the applied procedure 
is instrumental to ensure adequate TV dose delivery. Obviously the tight stereotactic 
dose distributions do not, in general tolerate TV displacements. Without setup cor-
rections, PTV margins should have been enlarged to minimize the risk of underdosing 
the tumor. 
On average, OAR dose distribution parameters were also close to planning, but the 
spread was much bigger than for the TV (compare Figs. 2 and 6a). OAR parameters 
could both be (substantially) higher and lower than planned. In strong contrast with 
the TV, the mean impact of setup corrections on OAR dose distribution parameters 
was virtually zero. Corrections could both positively and negatively (strongly) impact 
the OAR parameters, with comparable frequencies and magnitudes. Moreover, the 
dosimetric impact of corrections was independent from the magnitude of the setup 
error (Fig. 6b). Obviously, setup corrections are needed to ensure target coverage, and 
may fail to reduce OAR doses higher than planned, or may even (further) enhance 
these doses, owing to day-to-day anatomy deformations and/or rotations.
In this study, we did not account for dose variations caused by (residual) respiratory 
organ motion in the SBF. However, the expected impact of respiratory effects is very 
limited as reported by Wu et al. (22), because the breathing motion was reduced to 
≤ 5mm by means of abdominal compression. With a single-slice, spiral CT scanner, 
breathing motion may result in imaging artifacts, as discussed in a previous article 
(10), and may therefore contribute to setup error measurements based on CT. To 
reduce imaging artifacts, we acquire respiratory-correlated CT scans in our current 
liver SBRT practice. From this, we conclude that the magnitudes of daily setup errors 
found in this study are realistic and inherent to a SBRT treatment in an SBF. 
With the 14 patients in the study we were able to convincingly demonstrate that 
daily setup verifi cation and correction can prevent severe TV underdosage in some of 
the patients and that these setup corrections have a mixed impact on doses in OAR. 
To more precisely assess frequency distributions, this study should be extended with 
more patients.
Several approaches could potentially result in safer dose delivery, with better 
controlled-sparing of OARs. For treatment planning, OAR planning volumes could be 
designed, using the information on organ changes sampled from previously treated 
patients. International Commossion on Radiation Units and Measurements Report 62 
(1999) stressed the fact that movement and changes in shape and/or size of OARs, 
should be considered together with the setup uncertainties (23). It was advised to 
add a margin to compensate for these variations and uncertainties, which led to the 
concept of the OAR planning volume. However, neither dose criteria nor suggestions 
to calculate these margins for the different types of OARs were supplied. A few groups 
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have attempted to give a margin recipe, but limitations have been found, especially 
for parallel OARs (24, 25). A second solution could be a change in the current image-
guidance procedure by explicitly including OARs in the on-line image analyses. As a 
fi rst step, before dose delivery, one could fi rst establish the required tumor setup cor-
rection, followed by a dose calculation for the treatment CT scan, taking into account 
the setup correction. Accurate and fast evaluation of the simulated treatment dose 
distribution would however require segmented OARs in the treatment scan. Because 
manual delineation would be too time consuming, some sort of autosegmentation 
would be needed. In case of unacceptable OAR doses, one could ideally replan on 
line to adapt the planning to the patient anatomy of the day, (e.g. using a system for 
automated beam angle and weight optimization) (26). Until such a system for fast, 
on-line replanning is clinically available, occurrence of observed unacceptable OAR 
doses in the simulated treatment dose distribution could be a reason not to treat on 
the particular day. Optimal dose delivery could be achieved with an adaptive treat-
ment strategy, based on added fraction doses, assessed with a reliable nonrigid image 
registration technique (27). Ideally, nonrigid registration should be part of an on-line 
procedure, but also off-line application could improve dose delivery. In the latter, prior 
to each fraction, a new treatment plan could be designed, taking into account the 
added dose distributions delivered in the previous fractions.
CONCLUSIONS
With the tight dose distributions applied in liver SBRT, daily tumor setup correction 
is required to ensure coverage of the TV according to planning. OAR dose distribu-
tion parameters were on average close to planning, but showed a large variability in 
observed deviations. In contrast with the target, and caused by day-to-day anatomical 
variations, the mean impact setup corrections on OAR dose distributions was virtually 
zero, with large occasional positive and negative deviations. Moreover, for OARs, the 
dosimetric impact of corrections was independent from the magnitude of the setup 
error. Especially for dose-escalation protocols, development of adaptive treatment 
techniques and daily (on-line) replanning is warranted.
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ABSTRACT
Background: Stereotactic body radiation therapy (SBRT) is a treatment option for 
colorectal liver metastases. Local control, patient survival and toxicity were assessed in 
an experience of SBRT for colorectal liver metastases.
Methods: SBRT was delivered with curative intent to 20 consecutively treated patients 
with colorectal hepatic metastases who were candidates for neither resection nor 
radiofrequency ablation (RFA). The median number of metastases was 1 (range 1–3) 
and median size was 2.3 (range 0.7–6.2) cm. Toxicity was scored according to the 
Common Toxicity Criteria version 3.0. Local control rates were derived on tumour-
based analysis.
Results: Median follow-up was 26 (range 6–57) months. Local failure was observed 
in nine of 31 lesions after a median interval of 22 (range 12–52) months. Actuarial 
2-year local control and survival rates were 74 and 83 per cent respectively. Hepatic 
toxicity grade 2 or less was reported in 18 patients. Two patients had an episode of 
hepatic toxicity grade 3. 
Conclusion: SRBT is a treatment option for patients with colorectal liver metastases, 
who are not candidates for resection or RFA.
Alejandra Mendez bw.indd   82 03-02-11   13:23
83
Stereotactic body radiation therapy for colorectal liver metastases
6
INTRODUCTION
Colorectal cancer is a common malignancy and the second leading cause of cancer-
related death in the USA and Europe (1). Liver metastases develop in 50–70 per cent 
of patients with colorectal cancer during the course of the disease (2). Resection of 
colorectal liver metastases is still the ‘gold standard’ treatment, with 5-year survival 
rates ranging from 35 to 60 per cent in highly selected patients (3). Unfortunately, 
most patients are not eligible for surgery because of unfavourable tumour factors 
or poor general condition. Other local treatment techniques, among which radio-
frequency ablation (RFA) is the most widely used, offer a high rate of local control in 
inoperable patients with liver metastases (4, 5). However, RFA is preferably carried out 
for metastases that are smaller than 3 cm and not located in the proximity of major 
blood vessels, the main biliary tract or gallbladder, or just beneath the diaphragm (4).
Traditionally, radiotherapy has had a limited role in the treatment of intrahepatic 
malignancies owing to the low tolerance of the whole liver to irradiation. However, 
since the 1990s, groups from the Karolinska Hospital and Michigan Medical School 
(Ann Arbor) have demonstrated that large doses of conformal radiation can be deliv-
ered safely to localized targets in the liver (6, 7).
Stereotactic body radiation therapy (SBRT) is a non-invasive technique that delivers 
very large doses of radiation in a few fractions (8). Advances in tumour imaging, 
motion management, radiotherapy planning and dose delivery have allowed safe use 
of high-dose conformal radiation therapy in liver tumours (9). Several papers have 
reported outcomes after SBRT for liver metastases from various primary tumours 
(10–13). This study assessed local control, survival and toxicity after SBRT in a cohort 
of 20 patients with 31 liver metastases only from colorectal origin only.
METHODS
Patients with colorectal liver metastases who fulfi lled the following criteria were 
included in this study. Patients were evaluated by the Erasmus University MC Liver 
Board, which comprises hepatobiliary surgeons, medical oncologists, hepatologists, 
(interventional) radiologists and radiation oncologists, and were judged not eligible 
for surgery owing to unresectable metastases or poor general condition. Metastases 
were not suitable for RFA because of their proximity to vessels, bile ducts or the 
diaphragm. The Karnofsky index was at least 80 per cent. Maximum lesion size was 
6 cm and a maximum of three lesions was acceptable. Of patients with extrahepatic 
disease, only those with metastases eligible for curative treatment were eligible.
Alejandra Mendez bw.indd   83 03-02-11   13:23
Chapter 6
84
6
Radiotherapy
Patients were positioned in a stereotactic body frame (Elekta Oncology Systems, 
Stockholm, Sweden) with maximum tolerated abdominal compression to reduce re-
spiratory tumour motion for planning and treatment purposes (14). Three computed 
tomographies (CT) scans per patient were acquired: two contrast-enhanced scans in 
the arterial and venous phases for tumour defi nition and one large-volume scan for 
dose planning. The border of contrast enhancement was taken as the boundary of the 
metastasis. The tumour delineations were reviewed by an experienced radiologist. The 
tumour volume was then expanded with safety margins to compensate for the residual 
breathing motion and other uncertainties in tumour position, resulting in the planning 
target volume (PTV). Initially, equal safety margins were selected for all patients based 
on the Karolinska experience (5 mm in the left–right and anterior–posterior directions, 
and 10 mm in the craniocaudal direction) (14). Later, the margin was individualized in 
all three directions by measuring the residual motion of fi ducials implanted around the 
tumour using video fl uoroscopy registrations.
Up to June 2006, patients received three fractions of SBRT starting at 12.5 Gy, 
according to a phase I–II design (15). Thereafter, doses were escalated based on 
published data (16). Treatment plans were generated with the CadPlan treatment 
planning system (Varian Oncology Systems, Palo Alto, California, USA) with a median 
of 7 (4–10) beams. The dose was prescribed in such a way that at least 95 per cent of 
the PTV received a dose of 12.5 Gy (15 Gy in two patients). The length of the treat-
ment course was 5–6 days and the dose was delivered in fractions every other day.
Follow-up
Treatment results and side-effects were evaluated prospectively by clinical and labora-
tory examination and CT or magnetic resonance imaging at 1 and 3 months after 
irradiation, followed by further examinations every 3 months during the fi rst 2 years, 
and every 6 months thereafter. Toxicity was evaluated with the Common Toxicity 
Criteria (CTC), version 3.0, of the National Cancer Institute (http://ctep.cancer.gov). 
Local failure was defi ned as an increase in tumour size or tumour regrowth, with rates 
calculated on a tumour basis. Patients were monitored for local control even if distant 
or new liver metastases developed. Progressive disease included any intrahepatic or 
extrahepatic disease progression. If local failure or progressive disease was diagnosed, 
the date of recurrence was defi ned as the fi rst date on which an abnormality was 
recognized on CT. 
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Statistical analysis
To assess local control and survival, Kaplan–Meier analyses were generated using 
SPSS® version 15.0 software (SPSS, Chicago, Illinois, USA). The log rank test was used 
to identify variables associated with local control. 
RESULTS
Between December 2002 and July 2008, SBRT was administered to 20 consecutively 
treated patients with 31 lesions. In 19 patients the metastases were not amenable to 
resection or RFA owing to an unfavourable location and/or limited liver remnant. One 
patient had cardiac co-morbidity and non-invasive treatment was preferred. 
One patient received radiotherapy three times for recurrent lesions, fi rst elsewhere 
and the second and third times at this centre. Characteristics of the 31 metastases 
treated with SBRT are shown in Table 1. The median number of metastases was 1 
(range 1–3) and median size was 2.3 (range 0.7–6.2) cm.
Table 1. Patient, target and treatment characteristics of 20 patients with 31 hepatic metastases
Patients 20
 Sex ratio (M : F)
 Median (range) age (years)
Location of primary tumour
 Rectum
 Colon
15 : 5
72 (45–81)
5
15
Metastases 31
 Site (Couinaud segments)
 I
 II
 III
 IV
 IV/V
 V
 VI
 VI/VII
 VII
 VIII
Dose fractionation
 3 × 12.5 Gy
 3 × 15 Gy
3
0
1
3
1
3
1
1
5
13
29
2
Local control
Thirteen patients had SBRT as a second-line treatment after resection, isolated hepatic 
perfusion, RFA or SBRT elsewhere. None of the 20 patients received adjuvant che-
motherapy after SBRT. Fourteen patients had complete local control of all 22 lesions. 
Size of metastases was not a predictive factor of outcome. Local failure occurred in 
nine lesions in six patients after a median interval of 22 (range 12–52) months. One 
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patient who had two local failures in two lesions received chemotherapy, with an 
excellent response. This allowed extended liver surgery with curative intent. Three pa-
tients received palliative chemotherapy and died, and a further two patients were still 
receiving chemotherapy at the time of writing. Actuarial 1- and 2-year local control 
rates were 100 and 74 per cent respectively (Fig. 1a).
Fig. 1. a Local control rate and b 
overall survival after stereotactic 
body radiation therapy (SBRT).
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Overall survival
Nine patients had died after a median follow-up of 26 (range 6–57) months. Median 
time to progression of disease was 11 (range 1–52) months. Median overall survival 
was 34 months, and actuarial 1- and 2-year survival rates were 100 and 83 per cent 
respectively (Fig. 1b).
Toxicity
Eighteen patients had hepatic toxicity of grade 2 or less, whereas two patients had 
grade 3 toxicity (CTC version 3.0) with an increase in -glutamyl transferase level. 
One patient showed no changes in liver function parameters but developed portal 
hypertension syndrome with oesophageal varices (grade 1 toxicity) with one episode 
of melaena, and was treated conservatively. After the second radiation treatment this 
patient presented with hepatic toxicity and ascites (both grade 2), which responded 
well to temporary diuretic medication. Oesophageal bleeding evidenced by melaena 
occurred again, and the varices were treated with endoscopic band ligation. One 
patient became physically weak (grade 3) during the fi rst month after treatment 
but recovered spontaneously during the second month. Grade 2 pain owing to rib 
fractures occurred in one patient 10 months after irradiation of a subcapsular liver 
metastasis located in the vicinity of the ribs. No grade 4 or 5 (death), or stomach, 
bowel, kidney or spinal cord toxicity was found.
DISCUSSION
The present study has shown that SBRT for colorectal liver metastases can achieve 
2-year local control and survival rates of 74 and 83 per cent respectively with ac-
ceptable toxicity in patients who are not eligible for surgery or RFA. Three patients 
developed CTC toxicity grade 3, and late toxicity of grade 1 and 2 was reported in 
two patients. 
Resection should be regarded as the standard curative treatment in patients with 
hepatic metastases from colorectal cancer. However, only a minority of patients are 
suitable for liver resection (17). RFA has certain advantages over hepatic resection, 
such as a shorter hospital stay and a lower complication rate (5, 18), although the 
authors do not advocate it as an alternative to hepatic resection as it is associated 
with a higher local recurrence rate, with median time to local tumour progression 
between 4 and 9 months (19). RFA should be reserved for those in whom resection 
of all metastases is not possible (20). SBRT has been used for liver metastases that are 
unsuitable for or refractory to liver resection or RFA in an attempt to control disease 
locally. 
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SBRT involves the precise delivery of large doses of highly conformal radiation to 
extracranial targets using a small number of fractions. This treatment has several 
advantages over RFA. Owing to the heat-sink effect of large vessels, tissue close to 
the vessels is not amenable to RFA and major bile ducts are at increased risk of heat 
injury during ablation (18). To avoid these problems, centrally located liver lesions and 
metastases near large vessels may be treated with SBRT instead of RFA. SBRT is non-
invasive and can be offered to patients who are not eligible for invasive or minimal 
invasive interventions; it is also feasible in the outpatient setting, with no requirement 
for hospitalization or general anaesthesia. SBRT may be as effective as RFA for small 
tumours but may be less suitable for multiple tumours.
Herfarth and Debus (10) reported poorer local control of colorectal metastases than 
of tumours with other histology (45 versus 91 per cent after 18 months). This is in 
line with other studies that showed a lower local control or survival rate in patients 
with metastases from colorectal cancer compared with metastases from other primary 
tumours (12, 21). In contrast, Rusthoven and co-workers (22) reported an improved 
median survival of 32 months after treatment of liver metastases from favourable 
primaries (breast, colorectal, renal, carcinoid, gastrointestinal stromal tumour and 
sarcoma), compared with the median survival of 12 months for those from unfavour-
able primary sites (primary tumours of the lung, ovary and non-colorectal gastroin-
testinal malignancies). This raises the question of whether it is justifi ed to group liver 
metastases from primary colorectal cancer together with those from other primary 
cancers when evaluating the results of SBRT. Therefore, the present study focused on 
colorectal metastases only. 
A 2-year local control rate of 74 per cent was achieved for colorectal metastases 
generally treated with 3 × 12.5 Gy, with a median survival of 34 months. Previous stud-
ies describing the outcomes of SBRT for colorectal liver metastases are summarized in 
Table 2. Hoyer and colleagues (23) achieved a 2-year local control rate of 86 per cent 
after SBRT with 3 × 15 Gy for colorectal metastases in the liver, lung or suprarenal 
lymph nodes, or at two of these sites; median follow-up was 4.3 years. When liver me-
tastases were analysed separately, a 2-year local control rate of 78 per cent was noted 
(M. Hoyer, personal communication). This is in line with the present results, probably 
because the dose was similar in the two studies and median follow-up was adequate 
(more than 2 years). Rusthoven and co-workers (22) reported a 2-year local control 
rate of 92 per cent in liver metastases from a variety of primary tumours treated with 
36–60 Gy. This clinical experience is consistent with the knowledge that escalated 
doses of radiation are associated with improved local control and survival (21, 24). 
Dose escalation in the present cohort was limited owing to the small functional liver 
remnant because most patients had already undergone several partial liver resections 
and RFA procedures before SBRT. However, it is generally diffi cult to compare studies 
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on SBRT for liver tumours. Confl icting results regarding patient outcome might be 
explained by differences in patient selection criteria, site of metastases, dose prescrip-
tion, assessments of local failure or control, and duration of follow-up. In the present 
series median follow-up was 26 months and the median time to local failure was 22 
(range 12–52) months. Median follow-up in the series of Rusthoven et al. (22) was 
only 16 months, which may be too short to allow reliable estimation of local control.
Only a minority of patients with colorectal liver metastases in this clinic were treated 
with SBRT. The 20 patients in this study represent a negative selection as they were not 
eligible for surgery and/or RFA because of tumour size and/or location. Lesions were 
centrally located or near to biliary ducts and vessels. In this respect, these patients 
represent a group with a poor prognosis. 
Median survival of patients with stage IV colorectal cancer is about 24 months with 
modern chemotherapy (25, 26). In the present series, median survival was 34 months 
after SBRT; no serious acute toxicity was encountered in keeping with previous reports 
(10, 27, 28); and none of the patients received adjuvant chemotherapy. The low toxic-
ity after SBRT, and at least comparable survival to that after systemic chemotherapy, 
may justify its use in this patient group. The median time to disease progression after 
SBRT was 11 months, similar to that after liver resection in the authors’ experience 
(29). The lower median survival of 34 months after SBRT, compared with 44 months 
after partial liver resection, can be explained by the generally poorer prognosis of the 
cohort. 
Further research is needed to defi ne the role of SBRT within the treatment arma-
mentarium for colorectal liver metastases. A phase III trial has been proposed by this 
centre among others (International Liver Group) to compare SBRT in three fractions 
with RFA for the treatment of unresectable colorectal liver metastases up to 4 cm in 
diameter. Combined treatment with radiation sensitizers should be pursued in addi-
tion to randomized trials of SBRT for colorectal liver metastases. It has already been 
hypothesized that the combination of radiotherapy and angiogenesis inhibitors may 
Table 2. Reported local control rates after treatment of colorectal liver metastases with stereotactic body radiation 
therapy
Reference
No. of 
patients
No. of liver
lesions
Dose fractionation 
scheme
Median
follow-up
(months)
Actuarial
local control(%)
Actuarial
survival(%)
1 year 2 years 1 year 2 years
10 35 – 1×20–26Gy (80) 15* – 45† – –
13 – 23 3–4×7–12,5Gy (65) or 
1×26Gy (80)
15 88‡ 56‡ – –
11 20 – 7–20×2–6Gy (80) 15 – – 80‡ 26‡
12 40 – 6×4.6–10 (–) 11 – – 63 –
Present series 20 31 3×12.5–15Gy (65) 26 100 74 100 83
Values in parenthesis are percentage isodose. *Mean. †Eighteen month. ‡Data from fi gures.
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have a synergistic effect (30). Proper selection of patients for this treatment in high-
volume hepatobiliary centres with a multidisciplinary team is advocated.
In conclusion, SBRT is indicated in patients with unresectable colorectal liver metas-
tases or as a second-line therapy for recurrence after liver surgery (31). SBRT achieves 
adequate local control, and appears to be safe with respect to both acute and late 
toxicity in selected patients if normal tissue dose restrictions are respected.
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ABSTRACT
Purpose: To compare pathology macroscopic tumor dimensions with magnetic reso-
nance imaging (MRI) measurements, and to establish the microscopic tumor extension 
of colorectal liver metastases.
Methods and Materials: In a prospective pilot study we included patients with colorec-
tal liver metastases planned for surgery and eligible for MRI. A liver MRI was per-
formed within 48 hours before surgery. Directly after surgery, an MRI of the specimen 
was acquired to measure the degree of tumor shrinkage. The specimen was fi xed in 
formalin for 48 hours, and another MRI was performed to assess the specimen/tumor 
shrinkage. All MRI sequences were imported into our radiotherapy treatment planning 
system, where the tumor and the specimen were delineated. For the macroscopic 
pathology analyses photographs of the sliced specimens were used to delineate and 
reconstruct the tumor and the specimen volumes. Microscopic pathology analyses 
were conducted to assess the infi ltration depth of tumor cell nests.
Results: Between February 2009 and January 2010 we included 13 patients for analysis 
with 21 colorectal liver metastases. Specimen and tumor shrinkage after resection and 
fi xation was negligible. The best tumor volume correlations between MRI and pathol-
ogy were found for T1-weighted (w) echo gradient sequence (rs=0.99, slope=1.06), 
and the T2-w fast spin echo (FSE) single shot sequence (rs=0.99, slope=1.08), fol-
lowed by the T2-w FSE fat saturation sequence (rs=0.99, slope=1.23), and the T1-w 
gadolinium-enhanced sequence (rs=0.98, slope=1.24). We observed 39 tumor cell 
nests beyond the tumor border in 12 metastases. Microscopic extension was found 
between 0.2 and 10 mm from the main tumor, with 90% of the cases within 6mm.
Conclusions: MRI tumor dimensions showed a good agreement with the macroscopic 
pathology suggesting that MRI can be used for accurate tumor delineation. How-
ever, microscopic extensions found beyond the tumor border indicate that caution is 
needed in selecting appropriate tumor margins.
Acknowledgements: The authors thank Rob van Os, M.Sc., Anne van der Pool, M.D., 
Wouter Wunderink M.Sc., Paulette Prins, PhD, and Hans Joosten for their contribu-
tions.
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INTRODUCTION
Colorectal cancer is one of the leading causes of cancer-related mortality in men and 
women each year (1). During follow-up as many as 50 to 70% of patients diagnosed 
with colorectal cancer present liver involvement, which in half of these patients is the 
only site of recurrence (2).
Surgery is nowadays accepted as curative treatment option for colorectal liver 
metastases, but the majority of patients are not eligible for resection due to technical 
or medical reasons (2). When resection is not possible, radiofrequency ablation (RFA) 
is currently the most widely used treatment method (3). However, the location of 
metastases close to the large vessels, the main bile ducts, or the gallbladder poses a 
problem for adequate delivery of RFA. 
Over the past 20 years, stereotactic body radiation therapy (SBRT) has evolved as 
another local treatment option for primary and metastatic liver tumors. Local control 
rates have been increased by dose escalation protocols while acceptable levels of 
toxicity have been maintained (4,5). Nevertheless, to further optimize the treatment, 
the defi nition of the target volume should be improved. It is agreed that in SBRT for 
liver metastases, a safety margin should be added to the tumor visible in computed to-
mography (CT) and/or magnetic resonance imaging (MRI) to compensate for residual 
respiratory tumor motion and setup inaccuracies. However, there is still debate about 
the need for an extra margin to compensate for microscopic extension (ME), and a 
range of margins between 0 and 10 mm have been described in the literature (4-8). 
Neither has it been decided whether pre-treatment with chemotherapy might infl u-
ence the ME of the metastases. Similarly, to precisely defi ne the limits of the target 
volume, the correlation between macroscopic tumor dimensions visible in medical 
images and pathology should be evaluated. To our knowledge, literature reports on 
these subjects are scarce (9-12). 
The aims of this prospective study were to correlate pathology macroscopic tumor 
dimensions with MRI measurements, and to establish the microscopic tumor exten-
sion in a cohort of 20 colorectal liver metastases.
METHODS AND MATERIALS
Study design
Candidates for this prospective cohort study were diagnosed with colorectal liver 
metastases planned for surgery, and eligible to undergo an MRI scan. Patients with 
an insuffi cient renal function or estimated creatinine clearance <50ml/min were 
excluded. In total 20 colorectal liver metastases were estimated to be included in a 
period of approximately one year, 10 treated preoperatively with chemotherapy and 
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10 not. The study was approved by the Ethical Commission of Erasmus MC. Written 
informed consent was required.
Imaging
MRI was selected above CT as imaging modality because it is superior for the assess-
ment of malignant focal liver lesions (13,14).
Preoperative procedure
Within 48 hours before surgery, and preferably the day before, an MRI of the liver was 
performed with a 1.5T MR scanner (Signa HDxt, General Electrics, WI). This preopera-
tive MRI included a T2-weighted (w) fast spin echo (FSE) single shot (SS) sequence, a 
T1-w gradient echo (GE) sequence, a T1-w dynamic multiphasic gadolinium-enhanced 
(DMGE) sequence, and a T2-w FSE fat saturation (FS) sequence (Fig. 1A-D). The T1-w 
sequences and T2-w FSE SS sequences were carried out in breath hold (exhale). The 
T2-w FSE FS sequences were performed with the system triggered in expiration. The 
slice thickness for T1-w GE sequences and T2-w sequences was 8 mm, and for T1-w 
DMGE sequence it was 5 mm.
Surgery
No deviations were requested from the surgical approach decided up front, unless 
unexpected new lesions were observed, in which case the surgery was adapted to 
treat all lesions.
Directly after surgery
Once the specimen containing the tumor had been resected, it was sent to the radiol-
ogy department with a proper indication of the orientation in the body (superior/
inferior, left/right, and anterior/posterior) by three labeled small plastic tacks that were 
sewed into relevant positions of the specimen.
An MRI examination of the specimen was carried out directly after the resection and 
before fi xation. The aim was to investigate the possible shrinkage of the tumor directly 
after the specimen had been separated from the rest of the liver. The MRI equipment 
was the same as the one used to acquire the preoperative imaging. A combination of 
a T1-w GE sequence and a T2-w FSE FS sequence of the liver specimen was acquired 
with dedicated small fi eld of view (Fig. 1E-F). The slice thickness was 2 to 4 mm. After 
acquisition of MRI sequences, the specimen was fi xed in formalin.
Forty-eight hours after surgery
After 48 hours of fi xation, a second MRI of the resected specimen was performed with 
the same scanner and the same protocol as previously described. Figures 1G-H provide 
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sample images. The required acquisition of an MRI after 48 hours of fi xation restricted 
the possibility of receiving specimens to Mondays, Tuesdays and Wednesdays (until 
midday).
Fig. 1. Magnetic resonance imaging series and macroscopic pathology corresponding to a patient with a colorectal 
liver metastasis located in segment 4. Tumor is represented by T.
A: Preoperative T2-weighted fast spin echo (FSE) single shot sequence.
B: Preoperative T1-weighted gradient echo sequence.
C: Preoperative T1-weighted dynamic multiphasic gadolinium-enhanced sequence.
D: Preoperative T2-weighted FSE fat saturation sequence.
E: Postoperative T1-weighted gradient echo sequence.
F: Postoperative T2-weighted FSE fat saturation sequence.
G: Post-formalin T1-weighted gradient echo sequence.
H: Post-formalin T2-weighted FSE fat saturation sequence.
I: Sliced specimen.
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Macroscopic pathology analysis
On the same day of the postformalin MRI acquisition, we carried out an axial sec-
tioning of the specimen in slices of approximately 5 mm thickness, using a knife 
equipped with a sharp blade. Maximal diameters of the tumor and the specimen were 
measured together with the specimen weight. The specimen and later the consecutive 
sections were laid out for digital photography (Fig. 1I). The images were imported 
in MatLab (The MathWorks, Natick, MA) for further analysis. Establishment of the 
macroscopic pathologic tumor volume required delineated tumor contours and exact 
slice thicknesses. However, due to imperfections in sectioning of the specimen, the 
slice thickness needed for volume calculation was not exactly known and had to be 
estimated. For this purpose we divided the dimension of the specimen along which 
the slices were cut by the total number of slices. This procedure was validated in a 
subgroup of specimens by comparing the volume obtained from delineated speci-
men contours and the estimated slice thickness with the volume calculated from the 
measured weight of the specimen after applying a weight-to-volume correcting factor 
of 1.05 (average CT density of liver).
Microscopic pathology analysis 
Slices of the tumor and the surrounding liver parenchyma were taken for further 
microscopic analysis at the level of the percentiles 25, 50 and 75 of the superior/
inferior axis, regardless of tumor size. After cutting, slices were further fi xed in forma-
lin because the impact of the previous fi xation was limited to mainly the superfi cial 
areas of the specimen. Correction for potential additional shrinkage could not be 
quantifi ed. Later, the slices were embedded in paraffi n and cut with a microtome in 4 
μm sections, and stained with hematoxylin and eosin. Experienced hepatopathologists 
(JV, PEZ) evaluated the ME by light microscopy. If the main tumor was completely or 
partially surrounded by a fi brous pseudocapsule, the ME was considered to be the 
maximum distance from the outer border of the pseudocapsule to the outer boundary 
of the visible nests of tumor cells (15). If a fi brous pseudocapsule surrounding the main 
tumor was absent, we defi ned the tumor mass as the area where none or almost none 
of liver parenchyma interposed between tumor cells could be seen. The tumor border 
was defi ned as the line where liver tissue and nests of tumor cells interchanged. The 
ME was defi ned in this case as the distance from the main tumor border to the outer 
boundary of the visible nests of tumor cells (16).
Volume assessment of tumor and specimen in MRI 
Preoperative MRI series together with preformalin and postformalin sequences were 
imported into our radiotherapy planning system (FocalSim, version 4.3.3, CMS Inc, 
Maryland Heights, MO). Axial slices were used to contour and assess the volume of 
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the gross tumor/specimen in the image sets. Tumor contours were reviewed by an 
experienced liver radiologist (RSD).
Calculation of shrinkage factor 
The aim was to investigate the possible shrinkage of the tumor and when available the 
specimen, after the separation of the tumor/specimen from the rest of the liver, and 
after the fi xation of tumor/specimen in formalin. To calculate the shrinkage factors we 
assumed that the tumors were ellipsoids, and that the shrinkage was uniform in all 
three directions, resulting in the formula: 
Axis shrinkage factor = (Volume2/Volume1)
 (1/3)  (1)
Comparison of preoperative MRI with macroscopic pathology
For each of the four preoperative MRI sequences, delineated gross tumor volumes 
were compared with macroscopic pathology. Moreover, established MRI and pathol-
ogy volumes were converted into effective tumor radii, assuming the tumors were 
spherical.
Statistics
Descriptive statistics of variables were calculated (mean, standard deviation, minimum 
and maximum values). Linear regression analyses were performed to calculate the 
Spearman correlation coeffi cient (rs) and the regression coeffi cient, slope (s), of the 
assumed linear relationship between preoperative MRI and pathology volumes and 
effective radii. Correlation analyses using several independent variables were also car-
ried out to establish the presence and degree of correlation between pathology results 
and characteristics of the patient and the tumor. All other analyses were performed 
using non-parametric tests (signed-rank test and Kruskal-Wallis test).
RESULTS
Study population
Between February 2009 and January 2010 we enrolled 16 patients with colorectal 
liver metastases. Three patients were excluded from the analyses; two due to the 
lack of specimen photographs, and one due to a too thick slicing of the specimen. 
Patient characteristics of the 13 remaining patients with 21 metastases are presented 
in Table1. 
The chemotherapy regimen administered as treatment before surgery included 
oxaliplatin, capecitabine and bevacizumab.
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Table 1. Patient and tumor characteristics
Patients
Gender
 Male
 Female
8
5
Age (years) Mean (Min-Max) 63.9 (46-80)
Timing of developing metastases
 Synchronous
 Metachronous
Patients Metastases
3 5
10 16
Preoperative chemotherapy
 Yes
 No
Patients Metastases
5 10
8 11
Type of surgery
 Hemihepatectomy
 Segmentectomy
Patients Metastases
4 6
9 15
For all 21 metastases preoperative imaging was obtained without deviations in the 
protocol. For one small lesion (10 mm) in one patient, the tumor boundary could not 
be defi ned with certainty in three sequences of the preoperative MRI (T1-w EG, T2-w 
FSE SS and T2-w FSE FS). For another metastasis (30 mm) in another patient, the limits 
of the tumor could not be identifi ed properly in one sequence (T2-w FSE SS). 
In four metastases in two patients there were deviations from the protocol regard-
ing postoperative imaging. In these two patients the operation was concluded in the 
evening. This circumstance made it impossible to scan the specimens directly after 
surgery. For one patient, with two metastases, the specimen was scanned at the 
start of the next day, before fi xation in formalin. For the two specimens of the other 
patient, imaging before fi xation was not performed due to logistic reasons.
Postformalin imaging was available for all 21 metastases, although two metastases 
of one patient were not scanned on a Friday 48 hours after fi xation but on Monday 
morning because of a technical problem with the MRI scanner.
The pathology volume was not assessed in four metastases of two patients. All of 
these metastases had been pretreated with chemotherapy. Two of them were so small 
(6 mm and 10 mm diameter) that they were only present in one slice of the hemihepa-
tectomy making a volume calculation impossible. For the other two, it was extremely 
diffi cult to differentiate between tumor and normal liver parenchyma. Later these 
two metastases were described in the pathology report as mostly being composed of 
necrotic tissue. 
Descriptive statistics of the metastases volumes assessed by means of imaging and 
pathology are presented in Table 2.
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Table 2. Tumor volumes assessed by means of preoperative MRI and macroscopic pathology
N Mean (cc) SD (cc) Minimum (cc) Maximum (cc)
T1-w gradient echo 20 17.81 22.50 1 82
T2-w FSE single shot 19 18.59 23.5 1 84.80
T1-w gadolinium enhanced 21 20.22 26.12 1.2 95.40
T2-w FSE fat saturation 20 20.79 26.13 1.2 95.60
Pathology 17 18.35 22.15 0.5 76.90
w: weighted. FSE: fast spin echo.
Shrinkage factors
Calculation of the shrinkage factors was based on the T1-w EG sequence. Table 3 
presents an overview of the descriptive statistics for the calculated shrinkage factors 
of the tumor and the specimen volumes. Eighteen tumors and ten specimens (out of 
seventeen) were available for shrinkage factor calculations. One tumor could not be 
properly defi ned on the preoperative T1-w EG sequence. Two tumors/specimens had 
no postoperative imaging. Five specimens were not fully scanned beyond the tumor 
area. For both tumors and specimens shrinkage was very small (maximum 2%) and 
was neglected in further analyses.
Table 3. Tumor and specimen shrinkage factors from stage to stage
Tumor Specimen
N Mean SD P N Mean SD P
Preoperative / Postoperative 18 0.98 0.03 0.03 N.A N.A. N.A. N.A.
Postoperative / Post-formalin 18 1.00 0.01 0.22 10 1.00 0.01 0.23
N.A.: not applicable. SD: standard deviation.
P-values resulting from the signed-rank test calculation are presented.
Volume comparison
The mean differences between the tumor volumes measured in each of the four 
preoperative sequences and the volumes obtained by the macroscopic pathology are 
presented in Table 4. For all MRI sequences, the increase in mean volume compared 
to pathology was statistically signifi cant. The smallest mean difference was found for 
the T1-w EG sequence. As also presented in Table 4, the slope of the fi t-line between 
the volumes measured in this sequence and pathology was closest to one (s = 1.06). 
All MRI sequences correlated well with the pathology (rs≥0.98, Table 4). As shown in 
Table 5, differences between MRI and pathology in effective tumor radii were very 
small, especially for T1-w EG and T2-w FSE SS sequences with mean differences of 
0.06 and 0.07 cm respectively, and slope in both of 1.01. In Figure 2A, correlations 
between MRI- and pathology volumes are compared with the ideal correlation (slope 
= 1). Figure 2B shows similar data for effective tumor radii.
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Table 4. Mean differences between pre-operative MRI tumor volumes and corresponding macroscopic pathology
Difference N Mean (cc) SD (cc) P rs s
T1-w gradient echo - pathology 17 1.98 2.55 0.02 0.99 1.06
T2-w FSE single shot -pathology 16 2.38 2.94 0.01 0.99 1.08
T1-w gadolinium enhanced - pathology 17 5.92 6.18 <0.01 0.98 1.24
T2-w FSE fat saturation - pathology 17 5.39 5.92 <0.01 0.99 1.23
w: weighted. FSE: fast spin echo.
Standard deviations (SD) and P-values obtained from signed-rank tests. Spearman’s rank correlation coeffi cients (rs) 
and slopes (s) are also represented.
Table 5. Mean differences between pre-operative MRI tumor volumes and corresponding macroscopic pathology
Difference N Mean (cc) SD (cc) P rs s
T1-w gradient echo - pathology 17 1.98 2.55 0.02 0.99 1.06
T2-w FSE single shot -pathology 16 2.38 2.94 0.01 0.99 1.08
T1-w gadolinium enhanced - pathology 17 5.92 6.18 <0.01 0.98 1.24
T2-w FSE fat saturation - pathology 17 5.39 5.92 <0.01 0.99 1.23
w: weighted. FSE: fast spin echo. 
Standard deviations (SD) and P-values obtained from signed-rank tests. Spearman’s rank correlation coeffi cients (rs) 
and slopes (s) are also represented.
(A)
(B)
Fig. 2. Measured correlations between MRI 
and pathology tumor dimensions compared 
to the ideal correlation (dotted line). 
(A): Tumor volumes. 
(B):  Effective tumor radii, assuming a spheri-
cal tumor shape.
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Microscopic extension
A total of 39 tumor nests from 12 macroscopic metastases (57%) were found. Five 
of these metastases had been previously treated with chemotherapy and seven had 
not. Mean maximum infi ltration depth for the 39 tumor nests was 2.2 mm (range 
0.2-10). For almost 80% of the tumor nests the maximum infi ltration depth was 
found within 3 mm, and in almost 90% within 6 mm. Figure 3 shows a frequency 
histogram of tumor nests observed at various distances from the main tumor border. 
An example of a metastasis with two tumor nests is presented in Figures 4A and B. No 
signifi cant relationship was found between preoperative tumor volume and a deeper 
ME (p = 0.74, rs = 0.11). Neither could we fi nd a signifi cant relationship between 
patient or tumor characteristics, including preoperative chemotherapy, and presence 
or frequency of ME.
Fig. 3. Microscopic extension. Presented are the observed numbers of tumor nests as a function of the distance 
measured from the main tumor to the outer border of the tumor nest.
DISCUSSION
SBRT applied to unresectable colorectal liver metastases has demonstrated a good 
local control rate (17). To further optimize the treatment, we designed this study 
to compare pathology macroscopic tumor dimensions with MRI measurements, and 
to establish the microscopic tumor extension. MRI volumes and effective radii cor-
related well with macroscopic pathology (correlation close to 1 for all sequences). 
However, mean MRI volumes and effective tumor radii were statistically signifi cant 
enlarged compared to pathology for all sequences. Although statistically signifi cant, 
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the enlargements were small, especially for the T1-weighted (w) gradient echo (GE) 
and the T2-w fast spin echo (FSE) single shot (SS) sequences. The difference was larger 
for the T2-w FSE fat saturation (FS) and for the T1-w dynamic multiphasic gadolinium-
enhanced (DMGE) sequences. Probably we have included in our delineated tumor 
volumes some perilesional changes that are better depicted with these sequences 
(12,18). Semelka et al have correlated the presence of perilesional enhancement on 
gadolinium-enhanced MR images with pathology fi ndings for seven liver metastases 
(fi ve colorectal) (12). They found a difference of 10-13 mm in diameter between 
the precontrast and postcontrast series in three metastases (all colorectal), with the 
postcontrast series showing larger tumor dimensions due to prominent perilesional 
enhancement. Histopathologic analysis revealed the presence of a thick tumor border 
containing a combination of peritumoral desmoplastic reaction, peritumoral infl am-
mation, and vascular proliferation. However, the area with increased enhancement 
was systematically larger than the tumor border, suggesting that the enhancement 
(A)
(B)
Fig. 4. Microscopic extension evaluat-
ed using a light microscope (objective 
x 20).
(A): Tumor nest (TN) found adjacent 
to the capsule (C) that surrounds the 
main tumor (T). Liver parenchyma rep-
resented as L. 
(B): Tumor nest (TN) found at 3.5 mm 
from the capsule (C) that surrounds the 
main tumor (T). Liver parenchyma rep-
resented as L.
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extends beyond the tumor border into the surrounding liver. The authors presumed 
that this might have been caused by the infl ammatory effect around the tumor border 
which increases perfusion in the adjacent zone of hepatic parenchyma by releasing 
local factors that stimulate angiogenesis. This increases vascularity surrounding the 
tumor which will accumulate the contrast media (gadolinium) and thus demonstrate 
enhancement beyond the tumor. The same holds for the T2-w FSE FS sequence with 
demonstration of high signal intensity of the zone of increased vasculature surround-
ing the tumor. We detected a very small shrinkage of the tissue after the preoperative 
MRI measurement (2%) that might have increased the differences between preopera-
tive MRI and pathology results slightly. Although we did not correct for this factor, its 
impact on the present results is limited because the degree of shrinkage is less than 
the differences found between the MRI and the pathology results.
In a prospective study published in abstract format, Dawson et al compared the 
volumes in 4 patients with liver metastases assessed by preoperative (within 4 weeks 
of resection) CT, MRI, and positron emission tomography with macroscopic pathology 
(9). As in our study, the pathology gross target volume (GTV) was smaller than the im-
aging GTV in most of the patients (3 of 4). As well, in agreement with our results, the 
authors reported that pathology GTV correlated best with unenhanced MRI compared 
to venous enhanced for all patients. 
In a retrospective study published in abstract format, Gandhi et al compared the 
clinical tumor sizes in 27 patients with 36 colorectal liver metastases, assessed by 
preoperative CT or MRI, with the pathology size (10). The median number of days 
between imaging and surgery was 29 days. In 53% of tumors the pathology size was 
larger than the radiographic size, and smaller or equal in 47%. A possible explanation 
for this result might be tumor growth in the time between imaging and surgery.
As discussed above, nonenhanced MRI sequences showed the best correlation 
with the macroscopic pathology, and therefore they seem more adequate for tumor 
delineation, especially the T1-w EG sequence. Even though the T2-w FSE SS sequence 
showed a very high correlation between MRI and macroscopic pathology, the tumor 
boundary was easier to delineate in the other three series. Probably this observation 
is inherent to the image quality resulting from this sequence (18). In the liver MRI 
protocol at our institution this sequence serves mainly as a localizer and to character-
ize lesions as solid vs. nonsolid. The other series of our protocol are used to detect and 
further characterize liver lesions. The T2-w FSE FS and the postcontrast T1-w DMGE 
sequences may facilitate the tumor delineation but they may unnecessarily overesti-
mate the tumor volume by including other effects like peritumoral infl ammation or 
vascular proliferation. This may compensate for limited ME (a few millimeters) but it 
may not always be enough for the largest microscopic extension found in this study. 
Alejandra Mendez bw.indd   105 03-02-11   13:23
Chapter 7
106
7
The frequency and infi ltration depths of ME observed in the present study are in 
agreement with results reported in the literature. Prospective and retrospective surgi-
cal reports describe the presence of ME, although with a large variation in occurrence 
(2-58%) and in distance of infi ltration (0.15-38 mm) (19-22). In agreement with our 
results, Wakai et al reported that ME occurred more frequently (95% of the tumor 
nests) in the close zone (<1cm) than in the distant zone (≥1cm) of the gross tumor 
(22). Dawson et al (as mentioned above) also analyzed the ME beyond the GTV in 
4 patients (9). They found an extension of <1 mm for all cases. No frequency was 
reported. In agreement with these results, Gandhi et al (see above) also found measur-
able microscopic disease (mean 1.25 mm) in 7 of 24 (29%) analyzed tumors (10). 
No range was reported. The authors concluded that liver metastases from colorectal 
cancer do not seem to exhibit signifi cant ME. Both publications are in agreement with 
our results of fi nding ME, but our maximum and mean infi ltration depths were larger, 
even though most of the tumor nests that we found -almost 60%- were located 
within ≤1 mm from the tumor border. Ricke et al. described two categories of colorec-
tal liver metastases: round, with a regular margin, and oligonodular with an irregular 
margin (23). The latter included radiologically visible satellite lesions and showed an 
impaired local control after CT-guided brachytherapy. In general, all the metastases 
included in the present study showed a rather irregular shape, which made it diffi cult 
to establish a relationship between a more irregular tumor shape and a more frequent 
or deeper ME. 
This study was designed as a prospective pilot study to establish all the procedures 
needed to obtain a good clinicopathologic correlation and to measure the ME. As well, 
we tried to determine all factors that could negatively infl uence the accuracy of the 
measured results. The fi rst factor was the uncertainty of estimating the specimen slice 
thicknesses to reconstruct the tumor/specimen macroscopic pathology. To validate the 
procedure we used the data from a subgroup of specimens. Even though not all the 
specimens could be used for analysis, the correlation between the weight-corrected 
volume and the estimated volume of the specimen was good. The second factor 
was the unfeasibility of quantifying the potential additional shrinkage after cutting 
the specimen and taking slices for microscopic analysis. Hence, the ME measured in 
millimeters could therefore be underestimated. The third factor was the impossibility 
of excluding entirely that some of our tumor nests (observed in a two dimensional 
microscopic fi eld) were not in reality attached to the main tumor at another level, as 
some of the colorectal metastases demonstrated a very irregular border. We tried to 
correct to a maximum for this factor by inspecting thoroughly the slices located just 
above and beneath the one in which we observed the ME. The fourth factor was 
the limitation in the number of slices that we used for analyses (percentiles 25, 50 
and 75 of the superior/inferior axis). The ideal situation would have been to analyze 
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the whole liver tissue surrounding the main metastasis but because of the workload 
involved this was unfeasible in our study. However at the selected levels we examined 
the complete tumor border, irrespective of the size of the metastasis. Therefore, we 
conclude that the number of detected tumor nests is a lower limit of the real number. 
When converted into a histogram with relative frequencies, the histogram shown in 
Figure 3 may be considered as an estimate of the real relative histogram.
In a practical context our results could be considered as a prescription for extension 
of the high dose area around the main tumor, depending on the risk of error accepted 
(24). With a risk error of 10%, for example, it would be necessary to extend the high 
dose area by 6 mm, and with a risk error of 20 % an extension of 3 mm would be 
required. However, in part because of the size limitations, this study does not allow 
defi nitive and precise conclusions to be drawn about the need for or extent of an 
extra margin in SBRT planning to compensate for ME. The need for an extension of 
the high dose volume beyond the GTV does also not necessarily imply the need for an 
enhanced planning margin. Even with the most conformal techniques, there is often 
unavoidable delivery of a high dose beyond the gross tumor borders. Goitein et al 
reported on strategies for treating possible tumor extensions and which dose should 
be delivered (25). These authors suggested that when there is a low, but nonzero 
probability of disease in a particular region, then the delivery of a lower dose than that 
given to the GTV could be advantageous. Seidensticker et al published a proposal for 
a safety margin in brachytherapy for colorectal liver metastases (26). They estimated 
that to prevent the growth of micrometastases a threshold (single) dose of 15.4 Gy 
should be delivered. High local control rates have been published after treatment for 
SBRT of liver metastases with three fractions of 20 Gy, without adding extra margins 
to compensate for ME (5). Possibly, the limited conformality of external beam dose 
distributions, even for SBRT, allowed omission of a safety margin for ME. The need for 
an explicit enhancement of planning margins to cope with ME can also be obscured if 
generous (“safe”) margins are used to account for patient setup errors and tumor mo-
bility. The ongoing developments in increasing treatment precision (adaptive therapy, 
particle therapy) warrant investigations on ME of liver metastases to fully exploit these 
techniques for our future patients.
CONCLUSIONS
Our study demonstrated a good agreement between the tumor dimensions measured 
by MRI and the macroscopic pathology, suggesting that MRI can be used for accurate 
tumor delineation. However, microscopic extensions found beyond the tumor border 
indicate that caution is needed in selecting appropriate tumor margins.
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GENERAL DICUSSION AND FUTURE DIRECTIONS
Stereotactic body radiation therapy (SBRT) is a new cancer-treatment strategy that has 
evolved over the last twenty years. Unlike conventional external beam radiotherapy, 
which is usually delivered in 20-40 daily fractions of 1.8-2 Gy, SBRT applies high doses 
per fraction, generally around 6-20 Gy in a course of 1-6 fractions. In the past, such 
doses were impossible due to limitations in the dose delivery technology and to the 
potential toxicity associated with exposing large volumes of normal tissue to such 
doses. 
Recent technical developments in precise radiotherapy have made it possible to 
safely deliver high doses per fraction to tumors in different locations in the body (1). 
With SBRT we intentionally create hotspots within the radiation dose distribution, of 
up to - and even beyond - 50% or more of the prescribed dose. The purpose is to 
intensify the radiation dose inside the tumor while establishing a steep gradient of 
dose falloff at the interface between tumor and normal tissues (2).
Four essential characteristics of SBRT are secure immobilization, accurate reposition-
ing, proper accounting for internal organ motion, and an extremely conformal dosim-
etry. This therapy is used to treat well demarcated visible tumors in the liver, generally 
those up to 6 cm in diameter. Its intention is to totally disrupt the clonogenicity and 
the cellular functioning of the target tissues (3). 
The specifi c aim of this thesis is to assess the clinical outcomes of SBRT for liver 
tumors at our institution, to investigate the quality of SBRT, and to identify potential 
methods for its improvement.
In 2001, working on the basis of positive results reported by other groups, we 
developed a study protocol on SBRT for patients with liver metastases and hepatocel-
lular carcinoma (HCC) that were not eligible for surgery or RFA (4-6). The aim was to 
build up our experience and to assess the feasibility, toxicity, local control, and quality 
of life associated with this treatment. 
In Chapter 2 we report the outcomes of feasibility, toxicity and local control from 
this phase I-II trial. The prescribed doses used in this study were selected on the basis 
of the experience of Wulf et al. and Blomgren et al. We demonstrated that, although 
this treatment, was both resources-intensive and time consuming, it was feasible at 
our institution. In agreement with other studies, we showed that we could achieve an 
encouraging local control rate of 86% at two years for liver metastases and of 75% 
for HCC. 
The lower tumor control achieved in the HCC group was probably a consequence 
of the low dose (5 x 5 Gy) delivered to those patients with cirrhosis and large tumors; 
in contrast, all HCC treated with 3 x 12.5 Gy remained locally controlled. A clear dose 
relationship for HCC had already been established by Dawson et al. and Park et al. 
(7, 8). 
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A recent SBRT study has demonstrated excellent local control rates and good clinical 
tolerance at high radiation doses (3 x 12-16 Gy) in patients with HCC and Child-Pugh 
A cirrhosis (9). Other SBRT studies have also reported high rates of local control for 
HCC with acceptable toxicity (10-13). 
A point of concern in our study was the hepatic toxicity associated with SBRT in the 
presence of cirrhosis Child-Pugh grade B. Various authors including Cheng et al. and 
Liang et al. showed that cirrhosis Child-Pugh grade B was associated with a higher 
susceptibility to radiation-induced liver disease (RILD) (14-16). Other authors have also 
encountered limiting toxicity within this patient group (9). Because liver function is 
substantially deteriorated in these patients, it may not be acceptable in this population 
to use dose parameters that could infl uence the development of RILD modelled by 
the group from Michigan, whose patient population did not include patients with 
substantial alteration of the liver function (17). 
After the closure and analysis of the phase I-II study in 2006 we decided to treat 
only HCC patients with Child-Pugh grade A cirrhosis. Using the Michigan group 
parameters, we started calculating the normal tissue complication probability (NTCP) 
associated with the treatment, allowing for a maximum value of less than 5%. On the 
basis of this value, and independently of the tumor size, we now deliver 3 x 12.5 Gy at 
the 65% isodose or 6 x 8-9 Gy at the 80% isodose. Since the NTCP model is sensitive 
to high dose values that are enhanced by hypofractionation, we choose the latter 
fractionation scheme when the NTCP value is ≥5%, with the treatment consisting of 
three fractions. Options for raising the dose in this patient group have been reported 
and should be validated in our own population in future trials. 
Promising clinical benefi ts might be obtained through concomitant or sequential 
combinations of SBRT and Sorafenib for non-resectable HCC (18). Study protocols 
have been developed and trials have been open for inclusion of patients (19, 20). A 
systematic review and meta-analysis showed that the combination of transarterial 
chemoembolisation (TACE) with 3D conformal radiotherapy had greater therapeutic 
benefi ts than TACE alone (21). These encouraging results have led to the design of 
several studies to further explore the association of TACE with high biological doses 
delivered by SBRT (22).
While we observed limited hepatic toxicity within the metastases group during our 
phase I-II study, even lower toxicity rates were reported by the Colorado group from 
a phase I-II trial which proposed that at least 700 ml of normal liver should receive 
a total dose of less than 15 Gy (23, 24). Our own constraint was that 50% of the 
liver (including CTV) should receive a dose of 15 Gy or less. Additional review of 
patients with hepatic toxicity showed that sparing even more than 50% of the liver 
did not always correspond with at least 700 ml, but with a smaller volume. The 700ml 
constraint may be more suited to preserving enough functional organ parenchyma 
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and to preventing toxicity, particularly in small livers. Since 2006 we have introduced 
this value as our new liver constraint. 
Dose-escalation studies in this patient group have shown that local control was 
higher with a delivered higher dose (7, 25, 26). On the basis of these fi ndings, we have 
raised the treatment doses for liver metastases at our institution to 3x12.5-16.75 Gy 
at the 67% isodose. This prescription isodose was chosen between different European 
institutions involved in organizing a treatment protocol for a phase III randomized trial 
to compare SBRT with RFA for colorectal liver metastases (Karolinska Hospital, Aarhus 
University Hospital, and Erasmus MC). 
Quality of life is an important health parameter that provides clinicians and patients 
with useful information about a treatment’s impact on health status. In Chapter 3 we 
analyze the impact of SBRT on the quality of life of patients included in the phase I-II 
trial. In addition to a disease-specifi c questionnaire, the European Organization for 
Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ 
C-30), we used two generic quality of life instruments, Euro-QoL-5D (EQ-5D) and the 
EuroQoL-Visual Analogue Scale (EQ-5D VAS). On the basis of the model proposed by 
Wilson and Cleary we analyzed quality of life at three levels: general health percep-
tions, functioning, and symptoms (27). General health perceptions were measured 
by using the EQ-5D health state index, EQ-5D VAS score, and QLQ-C30 global health 
status index. Functional and symptom status were evaluated using the EORTC C-30 
functional and symptom domains, respectively.
Although the mean values obtained at baseline were lower than those in the general 
Dutch population, general health perceptions remained quite stable after treatment. 
Compared to baseline, mean values corresponding to functional domains were also 
stable after treatment. Mean values corresponding to symptom domains were slightly 
higher after treatment although only fatigue at one month resulted in a signifi cant 
difference compared with baseline. This fact did not affect the subjective evaluation 
of quality of life. 
Although there have been few clinical studies on the impact of local liver treat-
ments, we tested the robustness of our results by comparing our fi ndings with the 
literature. Wietzke-Braun, who used the EORTC QLQ C-30 questionnaire to analyze 
the impact of ultrasound-guided interstitial thermotherapy on quality of life in pa-
tients with unresectable colorectal liver metastases, detected a signifi cant increase 
in symptoms regarding pain at one week but also at six months after treatment (28). 
They suggested this might be related to the local incision and insertion of the catheter. 
Langenhoff et al. analyzed quality of life after surgical treatment in three groups 
of patients with colorectal liver metastases (29). The fi rst group had undergone the 
planned resection of metastases, or, if resection alone was not possible, had been 
treated with local tumor ablation. The second group turned out to have inoperable 
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disease at laparotomy and had undergone exploratory laparotomy only, as no re-
section or local ablative therapy with curative intent was possible. The third group 
consisted of patients who had been referred for surgery, but had been judged to have 
inoperable disease and therefore not scheduled for surgery. 
Although the EQ-5D baseline was more or less similar to that in our group, the 
researchers found, unlike us, that EORTC scales were comparable to norm scores ob-
tained from the general population; it was suggested that these high scores might be 
due to a reframing process. A potential explanation for the different fi nding may be 
that, regardless of a reframing process, the outcome refl ects the fact that the patients 
referred to SBRT had already experienced an extensive variety of treatments, including 
one or more liver resections or RFA procedures, as well as different chemotherapy 
schemes. 
Another remarkable difference is that, unlike the third group of Langenhoff et al., 
whose scores at 6 months without treatment were lower than at baseline, we found 
no signifi cant decrease in quality of life domains six months after treatment with SBRT. 
This suggests that SBRT, like surgery or RFA, may help to maintain a patient’s quality of 
life. In a paper published later than ours, Shun et al. reported that, in agreement with 
our fi ndings, quality of life was stable in liver cancer patients treated with SBRT for 
the fi rst six weeks after SBRT relative to quality of life at baseline (pretreatment) (30). 
New studies including a large number of patients are necessary to validate our 
fi ndings and are already in preparation (RAS study) (22). 
Over recent years, the EORTC QLQ-C30 has been supplemented by additional two 
disease-specifi c questionnaires for liver tumors: one for liver metastases from colorec-
tal cancer (EORTC QLQ-LMC 21), and one for primary liver cancer (EORTC QLQ-HCC 
18). As these questionnaires are intended to provide us with valuable information 
about specifi c symptoms and psychosocial issues not included in the EORTC QLQ-C30, 
they should be utilized in future clinical trials.
In Chapter 4 we investigate the benefi t of computer-optimized noncoplanar beam 
setups for the stereotactic treatment of liver tumors using Cycle, an automated system 
developed in house for beam orientation and weight selection. This system was used 
to generate coplanar and noncoplanar plans to be compared with manually generated 
clinical plans. The main objective of using Cycle was to maximize the minimum dose 
in the planning target volume (PTV) measured by means of the DPTV,99% or the dose 
delivered to 99% of the PTV, without exceeding the clinically delivered mean liver 
dose and without violating the clinical constraints. 
Automatically optimized beam selection resulted in higher DPTV,99% values than the 
clinical plan for the same isocenter and mean normal liver doses, without violating the 
clinical constraints. Automatically selected noncoplanar beam setups also had a higher 
dose gradient between the PTV and the surrounding normal tissue region than the 
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automatically selected coplanar beam setups did. On average, the OARs were better 
spared with the optimized noncoplanar plan than with the optimized coplanar plan 
and with the clinical plan. 
Although Thomas et al. have reported that the use of noncoplanar beams for the 
treatment of liver tumors was favorable only where the PTV incorporated another 
OAR besides the liver, our study showed that applying non coplanar directions in the 
beam setup for every case had a clear advantage (31). One reason for these differ-
ent observations might be that, in our case, the noncoplanar beam directions were 
computer optimized for each individual patient. 
Cycle was clinically introduced for the treatment of liver tumors in early 2009. Since 
then several modifi cations have been performed to make the system faster and more 
fl exible and user friendly. Depending on the diffi culty of the case, the generation of 
a new plan by Cycle now takes 15-30 minutes. Later, the technician imports the plan 
fi le generated by Cycle into our current planning system XIO (CMS). In the worst-case 
scenario this procedure will take an additional two to six hours. For the time being, 
we have limited the maximum number of beams to 20. Cycle represents an important 
step forward for our department in the stereotactic radiotherapy treatment of liver 
tumors not only because it helps us to improve the quality of the plans but also 
because it reduces the workload during the treatment planning process.
Because SBRT delivers large radiation doses in a few fractions, high precision is re-
quired in tumor volume defi nition, daily setup and dose delivery to guarantee accurate 
targeting and low toxicity. Because day-to-day changes in the position of the liver may 
impair target coverage in SBRT, the tumor position is daily verifi ed using computed 
tomography (CT)-guided treatment procedures to adjust the treatment setup before 
dose delivery (32-34). 
Even in image-guided treatments, however, optimal sparing of organs at risk (OARs) 
according to the treatment plan is not guaranteed, as the translational setup cor-
rections are based fully on the tumor displacements measured, while motion of the 
OARs may be different due to anatomy deformations. In chapter 5 we investigate the 
effects of the daily setup corrections and day-to-day anatomy variations on the dose 
distribution of the target volume (TV) and the OARs. 
For this study we included the CT data sets corresponding to the planning and three 
treatment fractions of a group of treated patients. For each treatment scan, two dose 
distributions were calculated, one using the planned setup for the body frame, and 
one using the clinically applied setup derived from the tumor displacements mea-
sured. These two dose distributions were compared, and the clinically delivered dose 
distribution was compared with the planned dose distribution. 
We observed that setup corrections prevented underdosage of the TV during treat-
ment: without setup corrections, the mean target coverage would have decreased by 
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6.8% with respect to planning. After applying setup corrections, the mean difference 
was reduced to 1.7%. Although there were large positive and negative deviations 
in the OARs doses relative to planning, the tumor based setup corrections had on 
average no impact on these doses. 
Several approaches could potentially result in safer dose delivery to the OARs. For 
treatment planning, the planning volumes of the OARs could be designed taking in 
account the information on organ changes sampled from patients treated previously. 
ICRU Report 62 (1999) stressed that movement and changes in the shape and/or 
size of OARs should be considered together with the setup uncertainties (35). It was 
recommended that a margin should be added to compensate for these variations and 
uncertainties, which led to the concept of the planning organ at risk volume (PRV). 
However, the report supplied neither dose criteria nor suggestions for calculating 
these margins for the different types of OARs, with the consequence that the concept 
of planning volume of the OARs became of limited use. 
A second solution might be to change the current image-guidance procedure by 
including not only the target but also the OARs in the on-line image analysis. As a 
fi rst step, one could establish, before dose delivery, which tumor setup correction 
was required, and then calculate the dose distribution for the treatment CT scan. 
However, accurate and fast evaluation of the simulated treatment dose distribution 
would require segmented OARs in the treatment scan. As manual delineation would 
be too time consuming, some sort of auto-segmentation would be needed. In case of 
unacceptable OAR doses, one could ideally re-plan on-line to adapt the planning to 
the patient anatomy of the day, for example by using a system for automated beam 
angle and weight optimization (36). Optimal dose delivery could be achieved with an 
adaptive treatment strategy based on added fraction dose distributions, assessed with 
a reliable non-rigid image registration technique (37). Ideally, non-rigid registration 
should be part of an on-line procedure, but off-line application could also improve 
dose delivery. In the latter, a new treatment plan could be designed prior to each frac-
tion taking account of the added dose distributions delivered in the previous fractions. 
Currently several projects are under investigation at our institution in order to 
achieve a truly adaptive treatment for liver tumors. Three research areas deserve 
special mention: a system for automated body-anatomy segmentation, a non-rigid 
image registration method, and a fast system for beam selection and optimization 
that would allow for daily on-line planning. 
Chapter 5 presents long term clinical outcomes of SBRT for colorectal liver me-
tastases. This retrospective study was the fi rst published report on SBRT and liver 
metastases of only colorectal origin. 
We included for analysis 20 patients who had been treated between December 
2002 and July 2008 with 31 metastases that were not eligible for surgery or RFA. 
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Up to June 2006 patients had received three fractions of 12.5 Gy, according to our 
phase I-II study. Thereafter, doses were escalated based on published data from the 
University of Colorado (23, 24). Median follow-up was 26 months. 
Our results showed that SBRT can achieve a two year local control and survival rate 
of 74% and 83%, with acceptable toxicity. In a personal communication, Hoyer et al. 
reported a two year local control rate of 78% after SBRT with 3x15 Gy at the isocenter 
for colorectal liver metastases. This was in line with our own results, and probably 
refl ects the rather similar doses used in the two studies and the median follow up of 
more than two years. 
Among other authors, Herfarth and Debus reported a signifi cantly poorer local con-
trol of liver metastases from colorectal cancer than of tumors from other histologies, 
especially for patients treated previously with systemic therapy (38, 39). A possible 
explanation is that chemotherapy might select radioresistant cells. Wulf et al. also 
found worse two year local control from colorectal cancer than from other primaries 
(56% vs.74%) although in this case it was not signifi cant (26). More recently, another 
publication evaluated the role of frameless robotic radiosurgery for colorectal liver 
metastases showing a two year local control of 55% (40). In this study, pretreatment 
with chemotherapy was preferred although not required. Rusthoven et al. reported a 
two year local control of 92% after a median follow up of 16 months from a variety 
of primaries treated with 36-60 Gy (41). This clinical experience is consistent with 
the knowledge that escalated doses of radiation are associated with improved local 
control (7, 25, 26, 42). 
Median survival in our study was 34 months and two year survival was 83%. Lee 
et al. reported that patients with primary colorectal cancer may have poorer survival, 
although non signifi cant in univariate analysis, than other primaries such as breast 
(two year survival 59% vs. 38%) (43). In contrast, Rusthoven et al. found a signifi -
cantly better median survival of 32 months after treatment of liver metastases from 
favorable primaries (breast, colorectal, renal, carcinoid, GIST and sarcoma), against 12 
months for those from unfavorable primaries (lung, ovary, non-colorectal gastrointes-
tinal malignancies) (41). This raises the question of whether it is justifi ed to group for 
analysis metastases from primary colorectal cancer with those from other primaries. 
The differences observed in survival between studies may also be the result of patient 
selection criteria based on the presence of a more or less extended intrahepatic and 
extrahepatic disease.
With a median survival of 44 months, resection should be regarded as the standard 
curative treatment option in patients with hepatic metastases from colorectal cancer 
(44). However, only a minority of patients are eligible for resection. For those with 
unresectable liver metastases, RFA is the most widely used treatment technique, with 
median overall survival in this patient group of 35 months (range 24-59 months) 
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(45). With modern chemotherapy, median survival rates for patients with hepatic 
metastases are 24 months. In our study, however, median overall survival of patients 
with colorectal liver metastases not eligible for resection, nor for RFA, was 34 months 
after SBRT without serious toxicity. The lower median survival relative to surgery can 
be explained by the generally poor prognosis in our cohort of patients. 
Further research is needed to better defi ne the role of SBRT within the treatment 
options for unresectable colorectal liver metastases. A phase III trial to compare RFA 
with SBRT has been proposed by various centers, including ours (22). The trial has 
been already open at Karolinska Hospital. Accrual of patients in this study will be 
further increase most likely by Aarhus University Hospital and Erasmus MC. 
In order to further optimize the treatment of colorectal liver metastases with SBRT, 
the target volume defi nition needed to be improved. It is generally agreed that to 
compensate for residual respiratory tumor motion and setup inaccuracies, a safety 
margin should be added to the tumor visible in CT or magnetic resonance imaging 
(MRI). However, there is some debate on the need for an extra margin to compensate 
for microscopic extension (26, 41, 43, 46). 
Similarly, to precisely defi ne the limits of the target volume, it was necessary to 
evaluate the correlation between macroscopic tumor dimensions visible in medical 
images and pathology. For this purpose, we organized a prospective pilot study to 
correlate pathologic macroscopic tumor dimensions with MRI measurements, and to 
establish the microscopic extension in colorectal liver metastases. The results of this 
study are presented in Chapter 7. MRI was selected as imaging modality rather than 
CT, as it is superior for assessing malignant focal liver lesions (47). 
Sixteen patients with 21 colorectal metastases were analyzed. MRI volumes cor-
related well with microscopic pathology with a correlation factor (rs) of 0.99 for the 
T1-weighted echo gradient sequence, the T2-weighted fast spin echo (FSE) single 
shot sequence, and the T2-weighted FSE fat saturation sequence. The correlation 
for the T1-weighted dynamic multiphasic gadolinium-enhanced sequence was 0.98. 
Although statistically signifi cant, the mean differences between MRI and pathology 
volumes were small, especially for the T1-weighted echo gradient sequence (1.98 
cc) and the T2-weighted FSE single shot sequence (2.38 cc). The mean differences 
were larger for the T2-weighted FSE fat saturation sequence (5.39 cc) and for the 
T1-weighted dynamic multiphasic gadolinium-enhanced sequence (5.92 cc). Probably, 
we have included in our delineated tumor volumes some perilesional changes such as 
peritumoral infl ammation and vascular proliferation, which are better depicted with 
these sequences (48, 49). In agreement with our results, Dawson et al. reported that 
because pathology gross target volumes (GTV) correlated better with the unenhanced 
MRI than with the venous enhanced sequences, they seem more suitable for tumor 
delineation, especially the T1-weighted echo gradient sequence (50). Even though 
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the T2-weighted FSE single shot sequence also showed a very high correlation be-
tween MRI and macroscopic pathology, the tumor boundary was easier to delineate 
in the other three series. This observation is probably inherent to the image quality 
resulting from this sequence (48). Although the T2-weighted FSE fat saturation and 
the postcontrast T1-weighted gadolinium-enhanced sequences may facilitate tumor 
delineation, they may unnecessarily overestimate tumor volume by including other 
effects stated above. 
The second aim of the study was to assess the microscopic extension of colorectal 
liver metastases. We found a total of 39 tumor nests (microscopic extension) outside 
12 out of 21 metastases (57%). The mean maximum infi ltration depth was 2.2 mm 
(0.2-10 mm), almost 80% of the tumor nests being found within 3 mm. While our 
results about frequency and range of infi ltration depths were within the range of 
other results reported in the literature, our limitation in the number of slices used for 
analysis probably means that the number of tumor nests found in our study was a 
lower limit of the real number (50-54). Therefore, this study did not enable us to draw 
defi nitive and precise conclusions about the need for or extent of an extra margin in 
SBRT planning to compensate for microscopic extension. 
Neither does the need for an extension of the high dose volume beyond the GTV 
necessarily imply that an enhanced planning margin is needed. Even with the most 
conformal techniques, there is often unavoidable delivery of a high dose beyond the 
gross tumor borders. Moreover, the need for an explicit enhancement of planning 
margins to cope with microscopic extension can also be obscured when generous 
(“safe”) margins are used to account for patient setup errors and tumor mobility. 
The on-going developments in increasing treatment precision (adaptive therapy, 
particle therapy) warrant investigations on the microscopic extension of liver metas-
tases to fully exploit these techniques for our future patients. Greater accuracy in 
target defi nition is also essential for improving treatment precision. Systems to allow 
the incorporation of two other imaging modalities, MRI and PET-CT, into our current 
delineation procedure are of extreme importance and therefore under development.
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SUMM ARY 
This thesis describes the clinical outcomes of stereotactic body radiation therapy 
(SBRT) for liver tumors at our institution; it investigates both the quality of SBRT and 
potential methods for its improvement. 
Chapters 2 and 3 present the clinical results on toxicity, local control, and quality of 
life in a group of patients included in a phase I-II study. Patients who were considered 
to be candidates for SBRT had been diagnosed with hepatocellular carcinoma or liver 
metastases that were not eligible for other local treatments, including surgery or 
radiofrequency ablation (RFA). Patients with cirrhosis Child-Pugh grade A and B were 
included. 
Local control rates were encouraging, with rates for the whole group of 94% at one 
year and 82% at two years. Four patients had acute toxicity ≥ 3. Three patients with 
liver metastases presented acute toxicity grade 3; two of these had an asymptomatic 
elevation of gamma glutamyl transpherase, and one had asthenia. One patient with 
Child Pugh grade B had hepatic toxicity grade 5, indicating that caution is needed 
in patients with cirrhosis due to a preexisting deteriorated liver function and conse-
quently an increased risk of toxicity. 
Chapter 3 reports the impact of SBRT on the quality of life of the patients included 
in the phase I-II study. Assessment was based on two generic questionnaires and one 
cancer specifi c questionnaire. Points of measurement were directly before treatment 
and one, three, and six months afterwards. We found that on average SBRT was 
associated with no signifi cant change in the patient’s quality of life. 
Chapter 4 investigates the use of Cycle, an automated system developed in house for 
beam orientation and weight selection, to improve the stereotactic treatment of liver 
tumors. In a group of 8 patients we showed that computer-optimized noncoplanar 
beam setups resulted in plans that were more favorable not only than the optimized 
coplanar beam setups but also than the clinical plans. Sparing of the organs at risk 
was better, and the dose received by the 99% of the planning target volume (DPTV,99%) 
was higher, while maintaining the same isocenter dose. The automation enabled us to 
reduce the planning workload relative to the clinical plans.
Chapter 5 assesses the impact of daily translational setup corrections and the day-
to-day anatomic variations on dose in target and organs at risk (OARs). For this study 
we included the computed tomography (CT) data sets corresponding to the planning 
and the three treatment fractions of 24 patients. For each treatment scan, two dose 
distributions were calculated, one using the planned setup for the body frame, and 
one using the clinically applied setup derived from tumor displacements. We showed 
that to obtain proper target coverage, daily correction of the treatment setup is neces-
sary. Due to day-to-day anatomy deformations, there were large deviations in the 
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OARs dose distributions that occurred with respect to the planning. On average, the 
clinical setup corrections had no impact on these doses. 
Chapter 6 presents a clinical report of 20 patients with 31 colorectal liver metastases 
treated with SBRT. Actuarial local control and survival at two years were 74% and 
83%, indicating that SBRT can offer an adequate local control and survival in patients 
not eligible for resection or RFA. Three episodes of toxicity grade 3 were observed, 
two asymptomatic elevation of gamma glutamyl transpherase, and one asthenia, sug-
gesting that the toxicity rate was acceptable. Two of these three patients with toxicity 
had been included previously in our phase I-II study. 
Chapter 7 compares tumor measurements determined by magnetic resonance im-
aging (MRI) and by macroscopic pathology, and assesses of microscopic extension for 
a group of 21 colorectal liver metastases. MRI and pathology were highly correlated 
(correlation factor 0.98-0.99), particularly for the non enhanced sequences (0.99), 
suggesting that MRI can be used for accurate tumor delineation. We found 39 tumor 
cell nests in 12 metastases located between 0.2 and 10mm beyond the main tumor, 
with 90% of the cases within 6 mm. This indicates that caution is needed in selecting 
appropriate tumor margins.
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SAMENVATTING
Dit proefschrift beschrijft de klinische uitkomsten van stereotactische radiotherapie 
(SRT) voor levertumoren in ons instituut; zowel de kwaliteit van SRT en potentiële 
methoden voor verbeteringen van de techniek werden onderzocht.
De hoofdstukken 2 en 3 presenteren de klinische resultaten van toxiciteit, lokale 
controle en de kwaliteit van leven in een groep van patiënten geïncludeerd in een 
fase I-II studie. Deze patiënten waren gediagnosticeerd met hepatocellulair carcinoom 
of levermetastasen die niet in aanmerking kwamen voor andere lokale behandeling 
opties, zoals chirurgie of “radiofrequentie ablatie” (RFA). Patiënten met cirrose Child-
Pugh grade A en B waren geïncludeerd. 
De lokale controle was bemoedigend, met getallen voor de hele groep voor een 
jaar van 94% en voor twee jaar 82%. Vier patiënten hadden acute complicaties 
graad 3 of hoger. Drie patiënten met levermetastasen vertoonden acute graad 3 
complicaties; twee van hen hadden een asymptomatische verhoging van de gamma 
glutamyl transpherase en één had vermoeidheid. Eén patient met Child Pugh grade 
B had hepatische toxiciteit graad 5. Dit betekent dat voorzichtigheid is geboden bij 
patiënten met levercirrose omdat een verslechterde leverfunctie een verhoogde kans 
op complicaties geeft.
Hoofdstuk 3 rapporteert de invloed van SRT op de kwaliteit van leven van de pati-
enten in deze fase I-II studie.
De beoordeling was gebaseerd op twee algemene vragenlijsten en een kankerspe-
cifi eke vragenlijst. De lijsten werden ingevuld: direct voor de behandeling en een, drie 
en zes maanden na afl oop. Met SRT bleef de kwaliteit van leven van de patiënten 
onveranderd.
Hoofdstuk 4 onderzoekt de meerwaarde van een zelfontwikkeld programma (Cy-
cle) voor computeroptimalisatie van bundelhoeken en gewichten. In een groep van 
8 patiënten bleken de computergeoptimaliseerde niet-coplanaire plannen superieur 
aan geoptimaliseerde coplanaire plannen en de klinische plannen. Het sparen van 
risico-organen was beter en de afgegeven dosis aan 99% van het planning target 
volume (DPTV,99%) was hoger bij dezelfde dosis in het isocentrum. De automatisering 
van de procedure reduceerde de werklast bij het maken van klinische planningen.
Hoofdstuk 5 bestudeert de invloed van dagelijkse translationele correcties van ge-
meten fouten in de positionering van de tumor ten opzichte van de bestralingsbundels 
en van anatomie deformaties op de dosis in het doelgebied en de risico-organen. Voor 
elk van de 24 patiënten is gebruik gemaakt van de planning computertomografi e (CT) 
scan en van de scans gemaakt op de drie behandeldagen. Retrospectief werden voor 
elke behandeldag twee dosisverdelingen berekend, één voor de geplande positionering 
van het stereotactische frame en de ander voor de klinisch toegepaste gecorrigeerde 
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positionering, zoals afgeleid van de gemeten tumor verplaatsing. Aangetond werd 
dat dagelijkse positioneringcorrecties onvermijdelijk zijn om bij de toegepaste krappe 
marges tumoronderdosering te voorkomen. Als gevolg van optredende deformaties 
in de anatomie van patiënten werden in de risico-organen soms grote afwijkingen van 
de geplande dosisverdeling gezien. Gemiddeld genomen hadden de translationele 
positiecorrecties geen invloed hierop, positief noch negatief.
Hoofdstuk 6 presenteert de klinische resultaten van 20 patiënten met 31 colorectale 
levermetastasen behandeld met SRT. De actuariële lokale controle en overleving op 
twee jaar waren 74% en 83% dat aangeeft dat SRT een adequate lokale controle en 
overleving geeft voor patiënten die niet in aanmerking komen voor chirurgie of RFA. 
Slechts drie graad 3 complicaties werden gezien, tweemaal een asymptomatische 
verhoging van de glutamyl transpherase en één casus van vermoeidheid. Twee van 
deze drie patiënten met complicaties zijn eerder in onze fase I-II studie geïncludeerd.
Hoofdstuk 7 vergelijkt tumor volumes gemeten met magnetische resonantiebeld-
vorming (MRI) met macroscopische pathologie en bepaalt verder de microscopische 
uitbreiding voor 21 colorectale levermetastasen. MRI en pathologie waren sterk met 
elkaar gecorreleerd (correlatiefactor: 0.98-0.99), in het bijzonder de “non enhanced” 
sequenties (0.99). Dit suggereert dat MRI gebruikt kan worden voor nauwkeurige 
tumor intekening. We vonden 39 tumorcelnesten rond 12 metastasen op afstanden 
variërend van 0.2 tot 10mm. In 90% van de gevallen was de afstand kleiner of gelijk 
aan 6mm. Voorzichtigheid is geboden bij het kiezen van de tumormarge, zeker bij 
dosisverdelingen die de tumoren nauw omsluiten en een sterke dosisafval richting de 
gezonde weefsels hebben.
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